WO2005021001A1 - Combinations of a pyrimidine containing nnrti with rt inhibitors - Google Patents

Combinations of a pyrimidine containing nnrti with rt inhibitors Download PDF

Info

Publication number
WO2005021001A1
WO2005021001A1 PCT/EP2004/052028 EP2004052028W WO2005021001A1 WO 2005021001 A1 WO2005021001 A1 WO 2005021001A1 EP 2004052028 W EP2004052028 W EP 2004052028W WO 2005021001 A1 WO2005021001 A1 WO 2005021001A1
Authority
WO
WIPO (PCT)
Prior art keywords
reverse transcriptase
tmc278
transcriptase inhibitor
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/EP2004/052028
Other languages
French (fr)
Inventor
Paul Stoffels
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005021001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Priority to JP2006525150A priority Critical patent/JP5507791B2/en
Priority to EA200600522A priority patent/EA014840B1/en
Priority to CN2004800254267A priority patent/CN101060844B/en
Priority to US10/570,228 priority patent/US20080200435A1/en
Priority to PL04787096.9T priority patent/PL1663240T5/en
Priority to AP2006003551A priority patent/AP2109A/en
Priority to NZ545306A priority patent/NZ545306A/en
Priority to SI200432257T priority patent/SI1663240T2/en
Priority to KR1020137024817A priority patent/KR101638999B1/en
Priority to DK04787096.9T priority patent/DK1663240T4/en
Priority to EP04787096.9A priority patent/EP1663240B2/en
Priority to ES04787096T priority patent/ES2542017T5/en
Priority to MXPA06002437A priority patent/MXPA06002437A/en
Priority to AU2004268390A priority patent/AU2004268390B2/en
Priority to BRPI0414027-3A priority patent/BRPI0414027A/en
Priority to CA2537095A priority patent/CA2537095C/en
Publication of WO2005021001A1 publication Critical patent/WO2005021001A1/en
Priority to CA2577273A priority patent/CA2577273C/en
Priority to AU2005279158A priority patent/AU2005279158C1/en
Priority to EA200700534A priority patent/EA011036B1/en
Priority to AP2007003933A priority patent/AP2487A/en
Priority to SI200531539T priority patent/SI1789139T1/en
Priority to AU2005279157A priority patent/AU2005279157B2/en
Priority to MX2007002595A priority patent/MX2007002595A/en
Priority to AT05108086T priority patent/ATE508748T1/en
Priority to ES05108086T priority patent/ES2371442T7/en
Priority to BRPI0514861-8A priority patent/BRPI0514861A/en
Priority to RS20110355A priority patent/RS51923B2/en
Priority to EP05108086.9A priority patent/EP1632232B3/en
Priority to KR1020077006376A priority patent/KR101276571B1/en
Priority to SI200531339T priority patent/SI1632232T1/en
Priority to DK05108086.9T priority patent/DK1632232T6/en
Priority to CN201510012919.7A priority patent/CN104586850A/en
Priority to JP2007528885A priority patent/JP4922937B2/en
Priority to ES05779369T priority patent/ES2384715T3/en
Priority to DK05779369.7T priority patent/DK1789139T3/en
Priority to MEP-2011-144A priority patent/ME01246B/en
Priority to US11/219,163 priority patent/US7638522B2/en
Priority to PCT/EP2005/054341 priority patent/WO2006024667A1/en
Priority to CA2577288A priority patent/CA2577288C/en
Priority to PT05108086T priority patent/PT1632232E/en
Priority to CN2005800380936A priority patent/CN101068597B/en
Priority to BRPI0514871-5A priority patent/BRPI0514871A/en
Priority to AT05779369T priority patent/ATE550074T1/en
Priority to HRP20110563TT priority patent/HRP20110563T4/en
Priority to PCT/EP2005/054342 priority patent/WO2006024668A1/en
Priority to SG200905799-3A priority patent/SG155885A1/en
Priority to US11/574,452 priority patent/US20090215804A1/en
Priority to EP05779369A priority patent/EP1789139B1/en
Priority to PL05108086T priority patent/PL1632232T6/en
Priority to KR1020077006837A priority patent/KR101284361B1/en
Priority to JP2007528886A priority patent/JP4912309B2/en
Priority to MX2007002594A priority patent/MX2007002594A/en
Priority to EA200700536A priority patent/EA013686B1/en
Priority to IL173438A priority patent/IL173438A/en
Priority to NO20061374A priority patent/NO334877B1/en
Priority to HK06113340.4A priority patent/HK1092698A1/en
Priority to IL181650A priority patent/IL181650A/en
Priority to IL181649A priority patent/IL181649A0/en
Priority to NI200700068A priority patent/NI200700068A/en
Priority to NI200700069A priority patent/NI200700069A/en
Priority to CR9032A priority patent/CR9032A/en
Priority to NO20071745A priority patent/NO340654B1/en
Priority to NO20071720A priority patent/NO339788B1/en
Priority to HK08101831.3A priority patent/HK1112862A1/xx
Priority to US12/168,540 priority patent/US7956063B2/en
Priority to US12/574,881 priority patent/US8841310B2/en
Priority to US12/845,463 priority patent/US8101629B2/en
Priority to US13/040,465 priority patent/US20110150996A1/en
Priority to AU2011201123A priority patent/AU2011201123B2/en
Priority to IL213104A priority patent/IL213104A/en
Priority to HRP20120499TT priority patent/HRP20120499T1/en
Priority to US14/454,045 priority patent/US20140349971A1/en
Priority to NO2014031C priority patent/NO2014031I1/en
Priority to US14/744,501 priority patent/US20150283135A1/en
Priority to NL300781C priority patent/NL300781I2/nl
Priority to LU92853C priority patent/LU92853I2/en
Priority to LU92855C priority patent/LU92855I2/en
Priority to BE2015C053C priority patent/BE2015C053I2/fr
Priority to CY2015038C priority patent/CY2015038I2/en
Priority to NL300768C priority patent/NL300768I2/en
Priority to FR15C0071C priority patent/FR15C0071I2/en
Priority to CY2015039C priority patent/CY2015039I1/en
Priority to FR15C0073C priority patent/FR15C0073I2/en
Priority to HUS1500053C priority patent/HUS1500053I1/en
Priority to HUS1500052C priority patent/HUS1500052I1/en
Priority to HUS1500054C priority patent/HUS1500054I1/en
Priority to CY2015040C priority patent/CY2015040I2/en
Priority to LU92854C priority patent/LU92854I2/en
Priority to FR15C0072C priority patent/FR15C0072I2/en
Priority to HK15110805.7A priority patent/HK1210029A1/en
Priority to US15/383,076 priority patent/US20170100398A1/en
Priority to NO2016025C priority patent/NO2016025I1/no
Priority to FR16C1023C priority patent/FR16C1023I1/en
Priority to LTPA2016043C priority patent/LTPA2016043I1/en
Priority to CY2016049C priority patent/CY2016049I1/en
Priority to LTPA2016045C priority patent/LTPA2016045I1/en
Priority to HUS1600059C priority patent/HUS1600059I1/en
Priority to LTPA2015035C priority patent/LTC1663240I2/en
Priority to HUS1600060C priority patent/HUS1600060I1/en
Priority to CY2016051C priority patent/CY2016051I1/en
Priority to HUS1600058C priority patent/HUS1600058I1/en
Priority to LTPA2016042C priority patent/LTPA2016042I1/en
Priority to CY2016050C priority patent/CY2016050I1/en
Priority to HUS1600061C priority patent/HUS1600061I1/en
Priority to CY2016048C priority patent/CY2016048I1/en
Priority to NO2016026C priority patent/NO2016026I1/en
Priority to FIEP04787096.9T priority patent/FI1663240T4/en
Priority to FR16C1025C priority patent/FR16C1025I1/en
Priority to NO2017063C priority patent/NO2017063I1/en
Priority to NO2017065C priority patent/NO2017065I1/en
Priority to US15/852,181 priority patent/US20180116964A1/en
Priority to US15/950,548 priority patent/US20180228800A1/en
Priority to US16/360,693 priority patent/US20190216807A1/en
Priority to US16/784,404 priority patent/US20200171027A1/en
Priority to US17/472,870 priority patent/US20220008417A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
  • HAART therapy Highly Active Anti-Retroviral Therapy
  • NRTIs nucleoside reverse transcriptase inhibitors
  • NRTIs non-nucleoside reverse transcriptase inhibitors
  • NtRTIs nucleotide reverse transcriptase inhibitors
  • protease inhibitors and even the more recent fusion inhibitors is still a major cause of therapy failure.
  • half of the patients receiving anti-HIV combination therapy do not respond fully to the treatment, mainly because of resistance of the virus to one or more drugs used.
  • resistant virus is carried over to newly infected individuals, resulting in severely limited therapy options for these drug-naive patients.
  • the pharmacokinetic profile of many commercially available antiretrovirals does not allow relatively low therapeutic doses. Poor pharmacokinetic profiles often in combination with poor solubility properties of the antiretrovirals cause the AIDS patient to face a high pill burden which is particularly undesirable for drug-naive patients or first line therapy. Moreover, as a consequence of the AIDS virus even resisting antiretroviral combination therapy, a physician will boost the plasma levels of the active drugs in order for said antiretrovirals to regain effectivity against the mutated HIV viruses, the consequence of which is an even higher increase in pill burden.
  • Boosting plasma levels may also lead to an increased risk of non-compliance with the prescribed therapy and to increased side-effects.
  • WO 93/23021 describes therapeutic combinations for the treatment of HIV-infections comprising zidovudine and an agent serving to enhance the antiviral activity against HIV populations otherwise resistant to zidovudine.
  • WO 96/01110 describes a triple combination of zidovudine, lamivudine and loviride, the latter being a non-nucleoside RT inhibitor of the -APA class.
  • WO 03/016306 specifically discloses more than 250 pyrimidine derivative having HIV replication inliibiting properties that act as non-nucleoside RT inhibitors (NNRTIs) having the ability to inhibit the replication both wild-type and of mutant strains.
  • NNRTIs non-nucleoside RT inhibitors
  • One of said NNRTIs is 4-[[4-[[4-(2-cyanoetl ⁇ enyl)-2,6-dimethylphenyl]-amino]-2- pyrimidinyl] amino] -benzonitrile (herein referred to as TMC278).
  • TMC278 non-nucleoside RT inhibitors
  • WO 03/016306 also discloses the methods to synthesize these compounds. It further discloses combinations of said NNRTIs with other antiretrovirals, i.e.
  • suramine pentamidine, thymopentin, castanospermine, dextran (dextran sulfate), foscamet-sodium (trisodium phosphono formate), zidovudine (3'-azido-3'-deoxythymidine, AZT), didanosine (2',3'-di- deoxyinosine; ddl), zalcitabine (dideoxycytidine, ddC), lamivudine (2'-3'-dideoxy- 3'-thiacytidine, 3TC), stavudine (2',3'-didehydro-3'-deoxythymidine, d4T), abacavir, nevirapine (ll-cyclopropyl-5,ll-dihydro-4-methyl-6H-dipyrido-[3,2-b : 2',3'-e] [l,4]diazepin-6-one) 5 efavirenz, de
  • Another object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be administered once daily thus reducing the pill burden for the patient.
  • a further object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be co-formulated.
  • Yet a further object of the invention is to provide combinations of more that one therapeutically active antiretroviral drug wherein a therapeutically effective amount of each of the active antiretroviral drugs of the combinations can be co-formulated in one single pharmaceutical formulation.
  • Another object of the present invention is to provide combinations of more than one active antiretroviral drug which combinations can be used to prevent HIV transmission or infection in humans.
  • the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the first and second nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as specified herein.
  • the invention also concerns the use of the combinations specified herein as HIV inhibitors and the use thereof in the treatment of HIV infected patients or in the prevention of HIV transmission or infection.
  • TMC278 is a potent reverse transcriptase inhibitor that has an extremely high genetic barrier in combination with a favourable pharmacokinetic profile allowing once daily dosing. It was surprising to discover that TMC278 has all these properties together. This is unusual because one cannot predict what mutations will be selected in the HIV-1 genome by a given drug, whether the mutated virus will have any chance of survival under the pressure of the drug, how much drug is needed to limit or to suppress the recurrence of such mutated virus, and at what frequency such drug has to be given to maintain suppression of the development of a resistant virus that can break through the genetic barrier of the drug.
  • the term 'therapeutically effective HIV inhibitors at a dose that can be administered once daily' means that the HIV inhibitors are suitable for dosing every 24 hours.
  • the HIV inhibitors for use in the invention can be dosed every 24 hours.
  • TMC278 or 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]- amino] -benzonitrile is a known NNRTI, which can be prepared as described in
  • TMC278 can be used in base form or, which is preferred, as a suitable pharmaceutically acceptable salt form, in particular as an acid addition salt form.
  • the pharmaceutically acceptable addition salts are meant to comprise the therapeutically active non-toxic salt forms.
  • the acid addition salt forms can be obtained by treating the base form with appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
  • hydrochloric hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxy- propanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzene- sulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino- 2-hydroxybenzoic and the like acids.
  • Preferred for use in the present invention are the hydrohalic acid salts, in particular the hydrochloride salt.
  • TMC278 occurs in stereoisomeric forms, more in particular as E- and Z-isomeric forms. Both isomers may be used in the combinations of the present invention.
  • TMC278 Whenever reference is made herein to TMC278, the E- and the Z-form as well as any mixture of both forms are meant to be included.
  • a preferred form of TMC278 for use in the invention is the E-isomer, i.e. (E)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]- benzonitrile (hereinafter called E-TMC278).
  • E-TMC278 The Z-isomer of TMC278, i.e.
  • (Z)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]- benzonitrile (hereinafter called compound Z-TMC278) can also be used. It has relatively high potency against wild-type HIV-1 but is less active against single and double mutants in comparison to the E-isomer.
  • Table 1 shows the IC50 value in nM of the E and Z-isomer of TMC278.
  • E-TMC278 the pure E-isomer or any isomeric mixture of the E- and the Z-forms wherein the E- form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the E-form, or even more than 90% of the E-form.
  • E-form substantially free of the Z-form refers to E-Z-mixtures with no or almost no Z-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the E-form.
  • TMC278 i.e. Z-TMC278, the pure Z-isomer or any isomeric mixture of the Z- and the E-forms wherein the Z-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the Z-form, or even more than 90% of the Z-form.
  • Z-form substantially free of the E-form refers to E-Z-mixtures with no or almost no E-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the Z-form.
  • Z-TMC278 hydrochloride and specifically E-TMC278 hydrochloride are also meant to be included for use in this invention.
  • the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278.
  • TMC278 and the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
  • a combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278.
  • a combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278.
  • a triple combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278.
  • a triple combination is provided comprising (i)
  • TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
  • Preferred nucleotide reverse transcriptase inhibitors that can be used in the combinations subject of this invention include tenofovir and its prodrug tenofovir disoproxil fumarate.
  • Tenofovir is an adenosine nucleotide analogue currently commercially available with activity against retroviruses.
  • Tenofovir disoproxil fumarate (tenofovir DF) is a once- daily, orally administered prodrug of tenofovir.
  • tenofovir DF needs to be hydrolysed to the ANP analogue and then phosphorylated to the active diphosphate moiety [Arimilli et al Antiviral Chemistry and Chemotherapy 1997, 8 :6 (557-564); Fridland et al. Antiviral Research 1997, 34].
  • the prodrug After entry in to lymphocytes or macrophages, the prodrug is quantitatively converted to the parent analogue, tenofovir, and phosphorylated to mono- and diphosphate metabolites.
  • the cellular enzymes that are responsible for phosphorylation of this drug are adenylate kinase and nucleoside diphosphate kinase [Robbins et al. Antimicrobial Agents and Chemotherapy 1995, 39 : 10 (2304-2308); Robbins et al. Antimicrobial Agents and Chemotherapy ⁇ 1998, 42 :3 (612-617)].
  • tenofovir is efficiently phosphorylated in resting as well as cycling peripheral blood lymphocytes [Robbins et al. 1998].
  • Tenofovir can inhibit HIV-1 replication in different cell types that may target HIV, including primary human blood lymphocytes and macrophages [Perno et al. Antiviral Research 1992 (289-304); Perno et al. Molecular Pharmacology 1996, 50 :2 (359-366)].
  • the primary target of tenofovir diphosphate is reverse transcriptase (RT).
  • Tenofovir diphosphate is a competitive inhibitor for the incorporation of deoxyadenosine triphosphate into nascent proviral DNA chains. Inhibition of HIV-1 RT by tenofovir diphosphate has an inhibition constant of approximately 0.9 ⁇ M, and if the analogue is incorporated into the growing viral DNA chain it may terminate further chain elongation. Tenofovir inhibits viral RT much more effectively than it inhibits cellular DNA polymerases [Suo et al Journal of Biological Chemistry 1998, 273 :42 (2750-2758)]. The concentration required to inhibit the replication of various HIV-1 strains by 50% (EC50) in lymphocyte and macrophage cell types (MT-2, CEM, ACH8) ranges from 0.2 to 10 ⁇ M.
  • the antiviral effect is achieved at non-toxic doses of tenofovir (selectivity index ranging from 100 to 2000).
  • Tenofovir DF is currently available as 300 mg tablets to be taken once daily. Viral resistance to tenofovir in vitro emerges slowly.
  • a recombinant virus expressing the K65R mutation showed a 3 -fold decreased susceptibility to tenofovir in vitro [Cherrington et al. Interscience Conference on Antimicrobial Agents and Chemo- therapy 1997, 37th].
  • a combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) tenofovir disoproxil fumarate; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • Preferred nucleoside reverse transcriptase inhibitors that can be used in the combinations of this invention include abacavir or a pharmaceutically acceptable salt thereof, emtricitabine, racemic FTC and lamivudine (also named 3TC).
  • Emtricitabine or (-)-FTC is the left (-) rotatory enantiomeric form of racemic FTC or ( ⁇ )-cis-4-amino-5-fluoro-l-[2-(hydiOxymethyl)-l,3-oxathiolan-5-yl]-2(lH)- pyiimidinone (FTC). It is a commercially available nucleoside analogue and exhibits activity against HIV-1 [Hoong et al. Journal of Organic Chemistry 1992 (5563-5565); Jeong et al Journal of Medicinal Chemistry 1993, 36 :2 (181-195); Van Roey et al. Antiviral Chemistry and Chemotherapy 1993, 4 :6 (369-375].
  • the in vitro anti-HTV-1 activity of (-)-beta-enantiomer of FTC was reported to be 20-fold more than the (+)- beta-enantiomer, and the (+)-enantiomer was significantly more toxic than the (-)-enantiomer to myeloid progenitor cells [Schinazi et al Antimicrobial Agents and Chemotherapy 1992, 36 :11 (2423-2431)].
  • the potential for HIV-1 resistance to FTC was evaluated by serial passage of the virus in human PBMCs and MT-2 cells in the presence of increasing drug concentrations. Highly drug-resistant HIV-1 variants dominated the replicating virus population after two or more cycles of infection.
  • RT derived from drag-resistant viral particles was 15- to 50-fold less susceptible to the 5'-triphosphate of FTC compared with the enzyme from parental drug susceptible virus.
  • DNA sequence analysis of the RT gene amplified from resistant viruses consistently identified mutations at codon 184 from Met (ATG) to Val (GTG or GTA) [Schinazi et al Antimicrobial Agents and Chemotherapy 1993, 37 :4 (875-881); Tisdale et al Antiviral Research 1993, 20 :Suppl 1; Smith et al Journal of Virology 1997, 71 :3 (2357-2362); Harrer et al Journal of Infectious Diseases 1996, 173 :2 (476-479); Tisdale et al Proceedings of the National Academy of Sciences of the United States of America 1993, 90 :12 (5653-5656)]. Due to this observed single mutation in the
  • (-)-FTC YMDD of reverse transcriptase in the HIV- infected patients
  • (-)-FTC is not suitable for monotherapy and needs to be administered in combination with other antiretroviral agents to effectively treat patients infected with HIV.
  • Emtricitabine is available as 200 mg capsules to be taken once a day.
  • Lamivudine has the chemical name (-)-2',3'-dideoxy-3'-thiacytidine and is described for instance in EP-382 526 as an antiviral nucleoside analogue. It is also a well established and useful antiretroviral which is commercially available for instance as 150 mg oral tablets. Lamivudine is also commercially available in combination with zidovudine (300 mg zidovudine / 150 mg lamivudine), and in combination with lamivudine and abacavir sulfate (300 mg zidovudine / 150 mg lamivudine / equivalent of 300 mg abacavir).
  • Abacavir is a well established and useful antiretroviral which is commercially available for instance as an oral solution of abacavir sulfate in a strength equivalent to 20 mg abacavir base/ml, or as an oral tablet of abacavir sulfate in a strength equivalent to 300 mg abacavir base.
  • Abacavir sulfate is also commercially available in combination with lamivudine and zidovudine (300 mg zidovudine / 150 mg lamivudine / equivalent of 300 mg abacavir).
  • Abacavir is a carbocyclic nucleoside with potent and selective anti-HIV activity.
  • Abacavir in its optically active form is disclosed in EP-434 450.
  • the cis-isomer of abacavir with unspecified absolute stereochemical configuration is described in EP-349 242.
  • Abacavir is one of the most potent NRTI developed to date. An average reduction in viral load of more than 1.4 log 10 RNA copies/ml is observed after a short course of abacavir monotherapy. In vitro, resistant virus is not rapidly selected by abacavir. A significant decrease in susceptibility to abacavir in wild-type or zidovudine-resistant HIV-1 strains was not observed until after eight to ten passages in MT-4 cells.
  • a set of resistance mutations at HIV reverse transcriptase (RT) codons, 65R, 74V, 115F and or 184V, are selected during in vitro passage with abacavir, and a combination of these mutations was required to confer a 10-fold reduction in abacavir susceptibility in a laboratory strain of HIV.
  • the first mutation detected upon passage of HIV-1 in an increasing concentration of abacavir is Ml 84V, which confers only a 3 -fold decrease in HIV-1 susceptibility.
  • Phenotype resistance to 3TC and/or the presence of the 184V mutation does not prevent viral load response to abacavir therapy.
  • a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof, and (ii) emtricitabine, wherein TMC278 and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) lamivudine, wherein TMC278 and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt thereof, characterized in that, TMC278 and abacavir are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir sulfate, characterized in that, TMC278 and abacavir sulfate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) emtricitabine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) lamivudine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulfate, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulphate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) emtricitabine, and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and emtricitabine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) lamivudine and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and lamivudine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate; and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HTV inhibitors at a dose that can be administered once daily.
  • TMC278, emtricitabine, lamivudine, abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate, and tenofovir or its prodrug tenofovir disoproxil fumarate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • the double combinations of the present invention may contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents.
  • the triple combinations of the present invention may equally contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents.
  • any of these additional agents are therapeutically effective at a dose that can be administered once daily.
  • the active ingredients of the combinations of the present invention may be administered simultaneously, concurrently or sequentially. Simultaneous administration may be done by employing a unitary pharmaceutical formulation or separate pharmaceutical formulations. In general, the combinations may be administered by topical, oral, rectal, intravenous, subcutaneous or intramuscular routes. For first line therapy of HIV infection, simultaneous administration employing a unitary pharmaceutical formulation is preferred.
  • the invention also provides a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
  • a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
  • a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inliibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
  • a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
  • a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor other than the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
  • the active ingredients in the products of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
  • Particular embodiments are products as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
  • the products as mentioned above may contain separate formulations of the active ingredients, or two or where applicable more of the active ingredients may be co- formulated.
  • the invention provides pharmaceutical formulations containing a combination as specified herein and a suitable carrier.
  • a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and or the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • the invention further provides a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
  • the active ingredients in the pharmaceutical formulations of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HTV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
  • Particular embodiments are pharmaceutical formulations as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
  • the pharmaceutical formulations of the present invention may be formulated into various forms for different types of administration.
  • effective amounts of the active ingredients optionally in addition salt form, is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • the pharmaceutical formulations of the invention are preferably formulated in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the present combinations can be formulated in an oral tablet form further comprising pharmaceutically acceptable excipients having a weight ranging between 150 mg and 600 mg, suitable ranging between 200 and 400 mg.
  • Convenient oral tablet forms containing the active ingredients according to the present invention have a total nominal weight ranging between 200 mg and 1500 mg, suitably between 500 mg and 1250 mg, more suitable between 600 and 1100 mg.
  • An advantage of the pharmaceutical formulations of the invention resides in the fact that each of the ingredients of the present combinations can be co-formulated in one pharmaceutical formulation and do not have to be administered separately.
  • the daily therapeutic antiretroviral amount of the ingredients of the present combinations of such co-formulated single pharmaceutical form preferably is administered in a single unit dosage form but, if desired, also multiple unit dosage forms, such as two, three, four, five or even more unit dosage forms may be administered.
  • a physician will be able to determine the exact dosage to be given taking into account the severity of the patient's condition as well as the patient's weight, gender and possibly other parameters such as individual differences in absorption, biodistribution, metabolism and excretion rates for each drug as well as other factors known to those skilled in the art.
  • This invention also provides a method of treating HIV infected patients said method comprising administering a combination as specified herein.
  • a method of treating HIV infected patients comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor and or a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor and/or nucleotide reverse transcriptase inhibitor can be administered once daily.
  • a method of treating HIV infected patients comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor can be administered once daily.
  • a further aspect of this invention concerns a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleotide reverse transcriptase inhibitor can be administered once daily.
  • Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor can be administered once daily.
  • Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a second nucleoside reverse transcriptase inhibitor different from the former nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleoside reverse transcriptase inhibitors can be administered once daily.
  • the active ingredients in the methods of the invention are administered in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
  • Particular embodiments are methods as specified above wherein one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate, are administered.
  • specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate
  • One embodiment of the present invention relates to the present combinations for use as a medicine. Another embodiment relates to the combinations of the present invention for use in the manufacture of a medicament to treat HIV infected patients.
  • TMC278 is E-TMC287, or preferably TMC278 hydrochloride salt or more preferably E-TMC278 hydrochloride salt.
  • the combinations of this invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS related complex (ARC), progressive generalised lymphadenopathy (PGL) or AIDS related neurological conditions such as multiple sclerosis.
  • ARC AIDS related complex
  • PDL progressive generalised lymphadenopathy
  • AIDS related neurological conditions such as multiple sclerosis.
  • the present triple combination may be particularly useful for the treatment of drug-na ⁇ ve HIV infected patients.
  • the combinations of the invention are also useful for the prevention of HIV transmission or infection in humans, in particular sexual transmission.
  • the present invention relates to the use of combinations according to the present invention for the manufacture of a medicament for the prevention of HIV infection or transmission via sexual intercourse or related intimate contact between partners.
  • the invention also relates to a method of preventing HIV infection or transmission via sexual intercourse or related intimate contact between partners comprising administering to a subject in need thereof an effective amount of any of the combinations according to the present invention.
  • the respective daily dose for each of the active ingredients of a combination according to the present invention may range between 10 mg and 800 mg, preferably between 50 and 400 mg, more preferably between 50 and 300 mg, or between 100 and 300 mg.
  • the daily dose for TMC278 may range between 10 mg and 500 mg, preferably between 10 and 300, more preferably between 50 and 250 mg, still more preferably between 50 and 200 mg, e.g. about 100 mg.
  • the weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/10 to 10/1.
  • the weight ratio of each couple varies between 1/6 and 6/1, more suitably 1/4 and 4/1, preferably between 1/3 and 3/1, and more preferably between 1/2 and 2/1.
  • Table 2 lists some examples of the daily dose for each of the active ingredients in combinations of compound E-TMC278, emtricitabine and tenofovir.
  • Table 3 lists some examples of the daily dose for each of the active ingredients in combinations of TMC278, abacavir and lamivudine wherein the dose mentioned in the table for abacavir sulfate is the equivalent dose of abacavir base.
  • an interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 10 mg and 500 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base.
  • a daily dose ranging between 10 mg and 500 mg
  • a daily dose of 150 mg lamivudine a daily dose of 150 mg lamivudine
  • a daily dose of an equivalent of 300 mg abacavir base is formulated in a single pharmaceutical form.
  • Another interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 50 mg and 250 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base.
  • a daily dose ranging between 50 mg and 250 mg
  • a daily dose of 150 mg lamivudine a daily dose of 150 mg lamivudine
  • a daily dose of an equivalent of 300 mg abacavir base is formulated in a single pharmaceutical form.
  • the present invention also relates to a pharmaceutical composition in a form adapted to be applied to a site where sexual intercourse or related intimate contact can take place, such as the genitals, rectum, mouth, hands, lower abdomen, upper thighs, especially the vagina and mouth, comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of a combination according to the present invention.
  • a pharmaceutical composition in a form adapted to be applied to a site where sexual intercourse or related intimate contact can take place, such as the genitals, rectum, mouth, hands, lower abdomen, upper thighs, especially the vagina and mouth, comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of a combination according to the present invention.
  • a pharmaceutically acceptable carrier as active ingredients an effective amount of a combination according to the present invention.
  • compositions usually employed for being applied to the vagina, rectum, mouth and skin such as for example gels, jellies, creams, ointments, films, sponges, foams, intravaginal
  • an effective amount of each of the particular compounds of the triple combination as the active ingredients is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of administration.
  • a bioadhesive in particular a bioadhesive polymer.
  • a bioadhesive may be defined as a material that adheres to a live biological surface such as for example a mucus membrane or skin tissue.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of each of the compounds of the present triple combination characterized in that the pharmaceutical composition is bioadhesive to the site of application.
  • the site of application is the vagina, rectum, mouth or skin, most preferred is the vagina.
  • Immature monocyte derived dendritic cells represent a good model for interstitial dendritic cells, which are early targets during sexual HIV transmission and important initiators of the immune response.
  • These immMO-DC were used in "in vitro" models to test the prevention of HIV infection via sexual intercourse or related intimate contact between partners.
  • One such model is described in the experimental part and indicates that the TMC278 potently inhibits HIV replication in MO-DC/ CD4(+) T cell co- cultures.
  • Example 1 Pharmacokinetics of E-TMC278 A double-blind, randomized, placebo-controlled Phase I trial was designed to evaluate safety, tolerability, and ex-vivo pharmacokinetics of single doses of compound E- TMC278 in healthy male volunteers. Oral doses of 12.5, 25, and 50 mg were formulated in PEG 400 and taken with a standard meal. The pharmacokinetic results are shown in Table 4.
  • Table 4 shows that high and dose-proportional exposures were obtained.
  • the correlation coefficient for the 5 C max datapoints is 0.9897 and for the area under the curve values between 0 and 48 hours (AUCo- 48hr ) 0.9952.
  • Half- life of plasma concentrations ranged between 37 and 39 hours. The compound was well tolerated by the volunteers. No relevant adverse effects of the drug were noted.
  • Compound E-TMC278 was tested in a cell-based assay, using natural host cells of HIV.
  • MT-4 cells a cell line of human T cells
  • HIV-1 wild type or mutants
  • Cytotoxicity was determined in parallel with the antiviral activity so that the selectivity of the antiviral effect could be assessed.
  • Active compounds have to penetrate the cell membrane in order to interfere with replication steps inside the cell.
  • IC50 50% inhibitory concentration for inhibition of viral cytopathicity
  • CC50 50% cytotoxic concentration
  • the ratio CC50/IC50 also called the selectivity index, is an indication of the specificity of the antiviral effect.
  • Tested HIV strains included: Wild type (wt) HIV-1; a panel of single and double mutants, obtained by site-directed mutagenesis (SDM), and a panel of clinical isolates, selected for resistance against NNRTIs.
  • NNRTIs are highly selective inhibitors of HIV-1 but their current clinical use is limited by the rapid emergence of NNRTI (cross-) resistance. The rate of resistance emergence against compound E-TMC278 and the first generation NNRTIs nevirapine and efavirenz was compared in vitro.
  • MT4 cells were infected with wild type HIV-1 at high multiplicity of infection (>1 infectious virus per cell, to maximize the genetic diversity of the virus population) in the presence of various concentrations of compound E-TMC278 (40, 200, 1000 and
  • HIV-1 resistant to first generation NNRTIs
  • emergence of HIV-1, resistant to compound E-TMC278 was delayed or did not occur.
  • Compound E-TMC278 had little or no effect on cardiovascular and pulmonary parameters in vivo at plasma levels covering and exceeding the targeted plasma levels in man and at concentrations in vitro covering or exceeding the anti- viral concentration in vitro.
  • Example 3 In vitro models to test the ability of compound E-TMC278 to prevent HIV infection via sexual intercourse or related intimate contact between partners.
  • monocyte-derived dendritic cells were infected for MO-DC.
  • MO-DC monocyte-derived dendritic cells
  • test compound A serial dilution of a compound of formula (I) (test compound) was added to the MO- DC/ CD4(+) T cell co-cultures. Each experiment was done in 96-well plates, in which each cup contained 50 ⁇ l of MO-DC, 50 ⁇ l of CD4(+) T cells and lOO ⁇ l of test compound.
  • EC50 value was 0.55 nM.
  • Example 4 formulations Tablet formulation of the following composition: Emtricitabine 300 mg
  • the active ingredients and lactose are fluidised and sprayed with a solution of HPMC and polysorbate in water (at an equivalent of 120 ml/tablet). Subsequently crosspolyvidone is added, while still being fluidised, followed by magnesium stearate and talcum. The thus obtained granulate is compressed into 13 mm cylindrical tablets using standard compressing equipment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention concerns combinations of a pyrimidine containing NNRTI named TMC278 with nucleoside reverse transcriptase inhibitors such as emtricitabine, lamivudine or abacavir and/or nucleotide reverse transcriptase inhibitors such as tenofovir useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.

Description

COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS
Field of the Invention
The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
Background of the Invention
Despite the fact that significant progress has been made by the introduction of HAART therapy (Highly Active Anti-Retroviral Therapy), resistance of the HIV virus against nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), protease inhibitors and even the more recent fusion inhibitors is still a major cause of therapy failure. For instance, half of the patients receiving anti-HIV combination therapy do not respond fully to the treatment, mainly because of resistance of the virus to one or more drugs used. Moreover, it has been shown that resistant virus is carried over to newly infected individuals, resulting in severely limited therapy options for these drug-naive patients. On the International AIDS Conference in Paris in July 2003, researchers released that the biggest study so far of resistance to AIDS drugs finds that about 10 percent of all newly infected people in Europe have drug-resistant strains. Smaller tests to determine the spread of resistance have been done in the high-risk city center of San Francisco. This test showed the highest level of resistance at 27 percent.
The pharmacokinetic profile of many commercially available antiretrovirals does not allow relatively low therapeutic doses. Poor pharmacokinetic profiles often in combination with poor solubility properties of the antiretrovirals cause the AIDS patient to face a high pill burden which is particularly undesirable for drug-naive patients or first line therapy. Moreover, as a consequence of the AIDS virus even resisting antiretroviral combination therapy, a physician will boost the plasma levels of the active drugs in order for said antiretrovirals to regain effectivity against the mutated HIV viruses, the consequence of which is an even higher increase in pill burden.
Boosting plasma levels may also lead to an increased risk of non-compliance with the prescribed therapy and to increased side-effects.
Several attempts have been made to date to design combination regimens. For instance, the combination of lamivudine (a nucleoside RT inhibitor also named 3TC) at a 150 mg dose and zidovudine (a nucleotide RT inhibitor also named AZT) at a 300 mg dose, formulated in an oral tablet and dosed twice daily, or the combination of abacavir sulfate at a dose equivalent to 300 mg abacavir (a nucleoside RT inhibitor), lamivudine at a 150 mg dose and zidovudine at a 300 mg dose, formulated in an oral tablet and dosed twice daily.
WO 93/23021 describes therapeutic combinations for the treatment of HIV-infections comprising zidovudine and an agent serving to enhance the antiviral activity against HIV populations otherwise resistant to zidovudine.
WO 96/01110 describes a triple combination of zidovudine, lamivudine and loviride, the latter being a non-nucleoside RT inhibitor of the -APA class.
An overview of new antiretroviral drugs is given in Clinical Microbiology and Infection 2003, Vol. 9 : 3, pp. 186-193.
WO 03/016306 specifically discloses more than 250 pyrimidine derivative having HIV replication inliibiting properties that act as non-nucleoside RT inhibitors (NNRTIs) having the ability to inhibit the replication both wild-type and of mutant strains. One of said NNRTIs is 4-[[4-[[4-(2-cyanoetlιenyl)-2,6-dimethylphenyl]-amino]-2- pyrimidinyl] amino] -benzonitrile (herein referred to as TMC278). WO 03/016306 also discloses the methods to synthesize these compounds. It further discloses combinations of said NNRTIs with other antiretrovirals, i.e. suramine, pentamidine, thymopentin, castanospermine, dextran (dextran sulfate), foscamet-sodium (trisodium phosphono formate), zidovudine (3'-azido-3'-deoxythymidine, AZT), didanosine (2',3'-di- deoxyinosine; ddl), zalcitabine (dideoxycytidine, ddC), lamivudine (2'-3'-dideoxy- 3'-thiacytidine, 3TC), stavudine (2',3'-didehydro-3'-deoxythymidine, d4T), abacavir, nevirapine (ll-cyclopropyl-5,ll-dihydro-4-methyl-6H-dipyrido-[3,2-b : 2',3'-e] [l,4]diazepin-6-one)5 efavirenz, delavirdine, TMC120, TMC125, tenofovir,
(S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4,5,l-jk] [l,4]benzodiazepine-2(lH)-thione, -[(2-nitrophenyl)amino]-2,6-dichloro-benzene- acetamide, RO-5-3335, indinavir, ritonavir, saquinavir, lopinavir (ABT-378), nelfmavir, amprenavir, TMC126, BMS-232632, VX-175, T-20, T-1249. AMD-3100 and hydroxyurea.
Notwithstanding existing combination therapy, there is still a need for improved antiretroviral therapy, more particularly AIDS therapy. This need is particularly acute for therapy that is effective not only on wild type HIV virus, but also on the increasingly more common resistant HIV viruses. It is thus highly desirable especially for first line therapy to design a combination regimen with a low pill burden that limits or even suppresses the recurrence of drug resistant virus and which can be used and remains effective for a long term.
It is an object of the invention to provide combinations of more than one therapeutically effective antiretroviral drug, which combinations can be used as first line therapy in drug-naϊve patients for a long period of time.
It is also an object of the invention to provide combinations of more than one therapeutically effective antiretroviral drug in which the antiretroviral drugs have a complementary resistance profile thus creating a high resistance barrier and thus allowing a drug-naϊve patient to take the combinations for a long period of time.
Another object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be administered once daily thus reducing the pill burden for the patient.
A further object of the invention is to provide combinations of more than one therapeutically active antiretroviral drug wherein each of the active antiretroviral drugs of the combinations can be co-formulated.
Yet a further object of the invention is to provide combinations of more that one therapeutically active antiretroviral drug wherein a therapeutically effective amount of each of the active antiretroviral drugs of the combinations can be co-formulated in one single pharmaceutical formulation.
Another object of the present invention is to provide combinations of more than one active antiretroviral drug which combinations can be used to prevent HIV transmission or infection in humans.
All references cited herein are incorporated by reference.
Summaiy of the Invention
Thus in a first aspect, the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
Thus in a second aspect, the present invention provides a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In a third aspect there is provided a combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In a fourth aspect there is provided a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In a fifth aspect there is provided a triple combination comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the first and second nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as specified herein.
The invention also concerns the use of the combinations specified herein as HIV inhibitors and the use thereof in the treatment of HIV infected patients or in the prevention of HIV transmission or infection.
The invention is based on the finding that TMC278 is a potent reverse transcriptase inhibitor that has an extremely high genetic barrier in combination with a favourable pharmacokinetic profile allowing once daily dosing. It was surprising to discover that TMC278 has all these properties together. This is unusual because one cannot predict what mutations will be selected in the HIV-1 genome by a given drug, whether the mutated virus will have any chance of survival under the pressure of the drug, how much drug is needed to limit or to suppress the recurrence of such mutated virus, and at what frequency such drug has to be given to maintain suppression of the development of a resistant virus that can break through the genetic barrier of the drug.
Detailed Description of the Invention
As used herein the term 'therapeutically effective HIV inhibitors at a dose that can be administered once daily' means that the HIV inhibitors are suitable for dosing every 24 hours. The 'term suitable for dosing every 24 hours' means that the HIV inhibitors are such that they can be administered every 24 hours and give effective blood plasma concentrations of the active ingredients such that they are effective to suppress HIV infection over a period of 24 hours. The HIV inhibitors for use in the invention can be dosed every 24 hours.
TMC278 or 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]- amino] -benzonitrile is a known NNRTI, which can be prepared as described in
WO03/016306. TMC278 can be used in base form or, which is preferred, as a suitable pharmaceutically acceptable salt form, in particular as an acid addition salt form. The pharmaceutically acceptable addition salts are meant to comprise the therapeutically active non-toxic salt forms. The acid addition salt forms can be obtained by treating the base form with appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxy- propanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzene- sulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino- 2-hydroxybenzoic and the like acids. Preferred for use in the present invention are the hydrohalic acid salts, in particular the hydrochloride salt.
TMC278 occurs in stereoisomeric forms, more in particular as E- and Z-isomeric forms. Both isomers may be used in the combinations of the present invention.
Whenever reference is made herein to TMC278, the E- and the Z-form as well as any mixture of both forms are meant to be included. A preferred form of TMC278 for use in the invention is the E-isomer, i.e. (E)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]- benzonitrile (hereinafter called E-TMC278). The Z-isomer of TMC278, i.e. (Z)-4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]- benzonitrile (hereinafter called compound Z-TMC278) can also be used. It has relatively high potency against wild-type HIV-1 but is less active against single and double mutants in comparison to the E-isomer. Table 1 shows the IC50 value in nM of the E and Z-isomer of TMC278.
Table 1
Figure imgf000007_0001
Whenever reference is made herein to the E-form of TMC278 (i.e. E-TMC278), the pure E-isomer or any isomeric mixture of the E- and the Z-forms wherein the E- form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the E-form, or even more than 90% of the E-form. Of particular interest is the E-form substantially free of the Z-form. Substantially free in this context refers to E-Z-mixtures with no or almost no Z-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the E-form. Equally, whenever reference is made herein to the Z-form of
TMC278 (i.e. Z-TMC278), the pure Z-isomer or any isomeric mixture of the Z- and the E-forms wherein the Z-form is predominantly present is meant to be comprised, i.e. an isomeric mixture containing more than 50% or in particular more than 80% of the Z-form, or even more than 90% of the Z-form. Of particular interest is the Z-form substantially free of the E-form. Substantially free in this context refers to E-Z-mixtures with no or almost no E-form, e.g. isomeric mixtures containing as much as 90%, in particular 95% or even 98% or 99% of the Z-form. Also meant to be included for use in this invention are salts of the isomeric forms of TMC278, in particular the salts mentioned above. Of particular interest are Z-TMC278 hydrochloride and specifically E-TMC278 hydrochloride.
Advantageously, the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278. Of particular interest therefore is any combination specified herein wherein (1) TMC278 and the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside/nucleotide reverse transcriptase inhibitor or inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
Specifically, in one embodiment, a combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278. In another embodiment, a combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor selects mutations in the reverse transcriptase that do not cause resistance to TMC278.
In a preferred embodiment, a triple combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a nucleotide reverse transcriptase inhibitor, wherein (1) TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor select mutations in the reverse transcriptase that do not cause resistance to TMC278. In another preferred embodiment, a triple combination is provided comprising (i)
TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein (1) TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily and (2) the nucleoside reverse transcriptase inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
Preferred nucleotide reverse transcriptase inhibitors that can be used in the combinations subject of this invention include tenofovir and its prodrug tenofovir disoproxil fumarate.
Tenofovir is an adenosine nucleotide analogue currently commercially available with activity against retroviruses. Tenofovir disoproxil fumarate (tenofovir DF) is a once- daily, orally administered prodrug of tenofovir. For antiviral activity, tenofovir DF needs to be hydrolysed to the ANP analogue and then phosphorylated to the active diphosphate moiety [Arimilli et al Antiviral Chemistry and Chemotherapy 1997, 8 :6 (557-564); Fridland et al. Antiviral Research 1997, 34]. After entry in to lymphocytes or macrophages, the prodrug is quantitatively converted to the parent analogue, tenofovir, and phosphorylated to mono- and diphosphate metabolites. The cellular enzymes that are responsible for phosphorylation of this drug are adenylate kinase and nucleoside diphosphate kinase [Robbins et al. Antimicrobial Agents and Chemotherapy 1995, 39 : 10 (2304-2308); Robbins et al. Antimicrobial Agents and Chemotherapy^ 1998, 42 :3 (612-617)]. Unlike other nucleoside analogues, such as zidovudine or stavudine, both of whose phosphorylation is cell cycle-dependent, tenofovir is efficiently phosphorylated in resting as well as cycling peripheral blood lymphocytes [Robbins et al. 1998]. Tenofovir can inhibit HIV-1 replication in different cell types that may target HIV, including primary human blood lymphocytes and macrophages [Perno et al. Antiviral Research 1992 (289-304); Perno et al. Molecular Pharmacology 1996, 50 :2 (359-366)]. The primary target of tenofovir diphosphate is reverse transcriptase (RT). Tenofovir diphosphate is a competitive inhibitor for the incorporation of deoxyadenosine triphosphate into nascent proviral DNA chains. Inhibition of HIV-1 RT by tenofovir diphosphate has an inhibition constant of approximately 0.9 μM, and if the analogue is incorporated into the growing viral DNA chain it may terminate further chain elongation. Tenofovir inhibits viral RT much more effectively than it inhibits cellular DNA polymerases [Suo et al Journal of Biological Chemistry 1998, 273 :42 (2750-2758)]. The concentration required to inhibit the replication of various HIV-1 strains by 50% (EC50) in lymphocyte and macrophage cell types (MT-2, CEM, ACH8) ranges from 0.2 to 10 μM. The antiviral effect is achieved at non-toxic doses of tenofovir (selectivity index ranging from 100 to 2000). Tenofovir DF is currently available as 300 mg tablets to be taken once daily. Viral resistance to tenofovir in vitro emerges slowly. A recombinant virus expressing the K65R mutation showed a 3 -fold decreased susceptibility to tenofovir in vitro [Cherrington et al. Interscience Conference on Antimicrobial Agents and Chemo- therapy 1997, 37th]. Notably, clinical HIV strains expressing the Ml 84V lamivudine- associated resistance mutation on RT show wild-type or increased susceptibility to tenofovir in vitro, independent of changes in Ki for the mutant enzyme [Miller et al. Interscience Conference on Antimicrobial Agents and Chemotherapy 1998,]. Long- term treatment (5 to 15 weeks) of newborn rhesus macaques with tenofovir (doses of 30 mg/kg) starting 3 weeks after inoculation with simian immunodeficiency virus, resulted in emergence of SIV with approximately 5-fold decreased susceptibility to tenofovir [Van Rompay et al. Antimicrobial Agents and Chemotherapy 1996, 40 : 11 (2586-2591)]. This low level of resistance was associated with the appearance of the
K65R mutation.
In a preferred embodiment, a combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) tenofovir disoproxil fumarate; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
Preferred nucleoside reverse transcriptase inhibitors that can be used in the combinations of this invention include abacavir or a pharmaceutically acceptable salt thereof, emtricitabine, racemic FTC and lamivudine (also named 3TC).
Emtricitabine or (-)-FTC is the left (-) rotatory enantiomeric form of racemic FTC or (±)-cis-4-amino-5-fluoro-l-[2-(hydiOxymethyl)-l,3-oxathiolan-5-yl]-2(lH)- pyiimidinone (FTC). It is a commercially available nucleoside analogue and exhibits activity against HIV-1 [Hoong et al. Journal of Organic Chemistry 1992 (5563-5565); Jeong et al Journal of Medicinal Chemistry 1993, 36 :2 (181-195); Van Roey et al. Antiviral Chemistry and Chemotherapy 1993, 4 :6 (369-375]. The in vitro anti-HTV-1 activity of (-)-beta-enantiomer of FTC was reported to be 20-fold more than the (+)- beta-enantiomer, and the (+)-enantiomer was significantly more toxic than the (-)-enantiomer to myeloid progenitor cells [Schinazi et al Antimicrobial Agents and Chemotherapy 1992, 36 :11 (2423-2431)]. The potential for HIV-1 resistance to FTC was evaluated by serial passage of the virus in human PBMCs and MT-2 cells in the presence of increasing drug concentrations. Highly drug-resistant HIV-1 variants dominated the replicating virus population after two or more cycles of infection. RT derived from drag-resistant viral particles was 15- to 50-fold less susceptible to the 5'-triphosphate of FTC compared with the enzyme from parental drug susceptible virus. DNA sequence analysis of the RT gene amplified from resistant viruses consistently identified mutations at codon 184 from Met (ATG) to Val (GTG or GTA) [Schinazi et al Antimicrobial Agents and Chemotherapy 1993, 37 :4 (875-881); Tisdale et al Antiviral Research 1993, 20 :Suppl 1; Smith et al Journal of Virology 1997, 71 :3 (2357-2362); Harrer et al Journal of Infectious Diseases 1996, 173 :2 (476-479); Tisdale et al Proceedings of the National Academy of Sciences of the United States of America 1993, 90 :12 (5653-5656)]. Due to this observed single mutation in the
YMDD of reverse transcriptase in the HIV- infected patients, (-)-FTC is not suitable for monotherapy and needs to be administered in combination with other antiretroviral agents to effectively treat patients infected with HIV. Emtricitabine is available as 200 mg capsules to be taken once a day.
Lamivudine has the chemical name (-)-2',3'-dideoxy-3'-thiacytidine and is described for instance in EP-382 526 as an antiviral nucleoside analogue. It is also a well established and useful antiretroviral which is commercially available for instance as 150 mg oral tablets. Lamivudine is also commercially available in combination with zidovudine (300 mg zidovudine / 150 mg lamivudine), and in combination with lamivudine and abacavir sulfate (300 mg zidovudine / 150 mg lamivudine / equivalent of 300 mg abacavir).
Abacavir is a well established and useful antiretroviral which is commercially available for instance as an oral solution of abacavir sulfate in a strength equivalent to 20 mg abacavir base/ml, or as an oral tablet of abacavir sulfate in a strength equivalent to 300 mg abacavir base. Abacavir sulfate is also commercially available in combination with lamivudine and zidovudine (300 mg zidovudine / 150 mg lamivudine / equivalent of 300 mg abacavir).
Abacavir is a carbocyclic nucleoside with potent and selective anti-HIV activity. Abacavir in its optically active form is disclosed in EP-434 450. The cis-isomer of abacavir with unspecified absolute stereochemical configuration is described in EP-349 242. Abacavir is one of the most potent NRTI developed to date. An average reduction in viral load of more than 1.4 log 10 RNA copies/ml is observed after a short course of abacavir monotherapy. In vitro, resistant virus is not rapidly selected by abacavir. A significant decrease in susceptibility to abacavir in wild-type or zidovudine-resistant HIV-1 strains was not observed until after eight to ten passages in MT-4 cells. A set of resistance mutations at HIV reverse transcriptase (RT) codons, 65R, 74V, 115F and or 184V, are selected during in vitro passage with abacavir, and a combination of these mutations was required to confer a 10-fold reduction in abacavir susceptibility in a laboratory strain of HIV. The first mutation detected upon passage of HIV-1 in an increasing concentration of abacavir is Ml 84V, which confers only a 3 -fold decrease in HIV-1 susceptibility. Phenotype resistance to 3TC and/or the presence of the 184V mutation does not prevent viral load response to abacavir therapy. Resistance to multiple nucleosides is associated with a decreased or absent response to abacavir [Kumar et al Antimicrobial Agents and Chemotherapy 1999, 43:3 (603-608); Lanier et al International Conference on Retroviruses and Opportunistic Infections 1998, 5th:Chicago; posted on 16 April 1999].
In a preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof, and (ii) emtricitabine, wherein TMC278 and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In a preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) lamivudine, wherein TMC278 and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt thereof, characterized in that, TMC278 and abacavir are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir sulfate, characterized in that, TMC278 and abacavir sulfate are therapeutically effective HIV inhibitors at a dose that can be administered once daily. In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) emtricitabine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and emtricitabine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) lamivudine, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and lamivudine are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulfate, and (iii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor and abacavir or a pharmaceutically acceptable salt thereof, or preferably abacavir sulphate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) emtricitabine, and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and emtricitabine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) lamivudine and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and lamivudine and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In another preferred embodiment, a triple combination is provided comprising (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate; and (iii) tenofovir or its prodrug tenofovir disoproxil fumarate, wherein TMC278 and abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate and tenofovir or its prodrug tenofovir disoproxil fumarate are therapeutically effective HTV inhibitors at a dose that can be administered once daily.
The following preferred triple combinations are also included
(a) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with emtricitabine and tenofovir disoproxil fumarate;
(b) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with lamivudine and tenofovir disoproxil fumarate.
(c) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with abacavir sulfate and tenofovir disoproxil fumarate.
(d) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; with emtricitabine and lamivudine;
(e) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; emtricitabine and abacavir or a pharmaceutically acceptable salt thereof, preferably abacavir sulfate.
(f) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; abacavir or a pharmaceutically acceptable salt thereof, preferably abacavir sulfate and lamivudine.
In particular, in each of the combinations (a) - (f) the active ingredients, in particular
TMC278, emtricitabine, lamivudine, abacavir or a pharmaceutically acceptable salt form thereof, preferably abacavir sulfate, and tenofovir or its prodrug tenofovir disoproxil fumarate, are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
The double combinations of the present invention may contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents. The triple combinations of the present invention may equally contain one or more additional active ingredients, which can be agents useful for treating HIV infected patients or other active agents. Preferably any of these additional agents are therapeutically effective at a dose that can be administered once daily.
The active ingredients of the combinations of the present invention may be administered simultaneously, concurrently or sequentially. Simultaneous administration may be done by employing a unitary pharmaceutical formulation or separate pharmaceutical formulations. In general, the combinations may be administered by topical, oral, rectal, intravenous, subcutaneous or intramuscular routes. For first line therapy of HIV infection, simultaneous administration employing a unitary pharmaceutical formulation is preferred.
Thus, in another aspect there is provided a product containing a combination as specified herein as a combined preparation for simultaneous, separate or sequential use against HIV infection.
The invention also provides a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
In a further aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
In another aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inliibitor, wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
In another aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection. In another aspect there is provided a product containing (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor other than the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily; as a combined preparation for simultaneous, separate or sequential use against HIV infection.
The active ingredients in the products of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
Particular embodiments are products as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
The products as mentioned above may contain separate formulations of the active ingredients, or two or where applicable more of the active ingredients may be co- formulated.
In still a further aspect the invention provides pharmaceutical formulations containing a combination as specified herein and a suitable carrier.
In another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and or the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
The invention further provides a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In still another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inhibitor, wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In still another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor and the nucleotide reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
In still another aspect there is provided a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and as active ingredients (i) TMC278 or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor different from the nucleoside reverse transcriptase inhibitor of (ii); wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
The active ingredients in the pharmaceutical formulations of the invention are present in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HTV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
Particular embodiments are pharmaceutical formulations as specified above containing one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate.
The pharmaceutical formulations of the present invention may be formulated into various forms for different types of administration. To prepare the pharmaceutical formulations of this invention, effective amounts of the active ingredients, optionally in addition salt form, is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. The pharmaceutical formulations of the invention are preferably formulated in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the formulations in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
In one aspect of the invention, the present combinations can be formulated in an oral tablet form further comprising pharmaceutically acceptable excipients having a weight ranging between 150 mg and 600 mg, suitable ranging between 200 and 400 mg.
Convenient oral tablet forms containing the active ingredients according to the present invention have a total nominal weight ranging between 200 mg and 1500 mg, suitably between 500 mg and 1250 mg, more suitable between 600 and 1100 mg.
An advantage of the pharmaceutical formulations of the invention resides in the fact that each of the ingredients of the present combinations can be co-formulated in one pharmaceutical formulation and do not have to be administered separately. The daily therapeutic antiretroviral amount of the ingredients of the present combinations of such co-formulated single pharmaceutical form preferably is administered in a single unit dosage form but, if desired, also multiple unit dosage forms, such as two, three, four, five or even more unit dosage forms may be administered. A physician will be able to determine the exact dosage to be given taking into account the severity of the patient's condition as well as the patient's weight, gender and possibly other parameters such as individual differences in absorption, biodistribution, metabolism and excretion rates for each drug as well as other factors known to those skilled in the art. This invention also provides a method of treating HIV infected patients said method comprising administering a combination as specified herein.
Furthermore there is provided a method of treating HIV infected patients, said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor and or a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor and/or nucleotide reverse transcriptase inhibitor can be administered once daily.
Furthermore there is provided a method of treating HIV infected patients, said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleoside reverse transcriptase inhibitor can be administered once daily.
In a further aspect of this invention concerns a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278 and the nucleotide reverse transcriptase inhibitor can be administered once daily.
Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a nucleotide reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor can be administered once daily.
Still a further aspect of this invention comprises a method of treating HIV infected patients said method comprising administering TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, in combination with a nucleoside reverse transcriptase inhibitor, and a second nucleoside reverse transcriptase inhibitor different from the former nucleoside reverse transcriptase inhibitor, in which method a therapeutically effective amount of TMC278, the nucleoside reverse transcriptase inhibitors can be administered once daily. The active ingredients in the methods of the invention are administered in therapeutically effective amounts, the latter meaning an amount that is sufficient to exert a sufficient HIV inhibitory effect during a certain time period, i.e. the time period between each intake of the formulations, preferably for about 24 hours.
Particular embodiments are methods as specified above wherein one or more of the specific active ingredients mentioned herein such as emtricitabine, racemic FTC, lamivudin, tenofovir and its prodrug tenofovir disoproxil fumarate, are administered.
One embodiment of the present invention relates to the present combinations for use as a medicine. Another embodiment relates to the combinations of the present invention for use in the manufacture of a medicament to treat HIV infected patients.
Of particular interest are any of the combinations as specified herein, or any of the products, pharmaceutical formulations, unit dosage forms, methods and uses being based on said combinations, wherein TMC278 is E-TMC287, or preferably TMC278 hydrochloride salt or more preferably E-TMC278 hydrochloride salt.
The combinations of this invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS related complex (ARC), progressive generalised lymphadenopathy (PGL) or AIDS related neurological conditions such as multiple sclerosis. The present triple combination may be particularly useful for the treatment of drug-naϊve HIV infected patients.
The combinations of the invention are also useful for the prevention of HIV transmission or infection in humans, in particular sexual transmission. Thus, the present invention relates to the use of combinations according to the present invention for the manufacture of a medicament for the prevention of HIV infection or transmission via sexual intercourse or related intimate contact between partners. The invention also relates to a method of preventing HIV infection or transmission via sexual intercourse or related intimate contact between partners comprising administering to a subject in need thereof an effective amount of any of the combinations according to the present invention.
The respective daily dose for each of the active ingredients of a combination according to the present invention may range between 10 mg and 800 mg, preferably between 50 and 400 mg, more preferably between 50 and 300 mg, or between 100 and 300 mg. In particular, the daily dose for TMC278 may range between 10 mg and 500 mg, preferably between 10 and 300, more preferably between 50 and 250 mg, still more preferably between 50 and 200 mg, e.g. about 100 mg.
The weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/10 to 10/1. Suitably, the weight ratio of each couple varies between 1/6 and 6/1, more suitably 1/4 and 4/1, preferably between 1/3 and 3/1, and more preferably between 1/2 and 2/1.
Table 2 lists some examples of the daily dose for each of the active ingredients in combinations of compound E-TMC278, emtricitabine and tenofovir.
Figure imgf000021_0001
Table 3 lists some examples of the daily dose for each of the active ingredients in combinations of TMC278, abacavir and lamivudine wherein the dose mentioned in the table for abacavir sulfate is the equivalent dose of abacavir base.
Figure imgf000021_0002
Thus, an interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 10 mg and 500 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base. Suitably, such combination is formulated in a single pharmaceutical form.
Another interesting combination according to the present invention comprises compound E-(A) in a daily dose ranging between 50 mg and 250 mg, a daily dose of 150 mg lamivudine and a daily dose of an equivalent of 300 mg abacavir base. Suitably, such combination is formulated in a single pharmaceutical form.
The present invention also relates to a pharmaceutical composition in a form adapted to be applied to a site where sexual intercourse or related intimate contact can take place, such as the genitals, rectum, mouth, hands, lower abdomen, upper thighs, especially the vagina and mouth, comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of a combination according to the present invention. As appropriate special adapted compositions there may be cited all compositions usually employed for being applied to the vagina, rectum, mouth and skin such as for example gels, jellies, creams, ointments, films, sponges, foams, intravaginal rings, cervical caps, suppositories for rectal or vaginal application, vaginal or rectal or buccal tablets, mouthwashes. To prepare such pharmaceutical compositions, an effective amount of each of the particular compounds of the triple combination as the active ingredients is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of administration. In order to increase the residence time of such pharmaceutical composition at the site of administration, it may be advantageous to include in the composition a bioadhesive, in particular a bioadhesive polymer. A bioadhesive may be defined as a material that adheres to a live biological surface such as for example a mucus membrane or skin tissue.
Thus, the present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients an effective amount of each of the compounds of the present triple combination characterized in that the pharmaceutical composition is bioadhesive to the site of application. Preferably, the site of application is the vagina, rectum, mouth or skin, most preferred is the vagina.
Often RA et al in Journal of Virology (2000), 74(20), 9771-9775 and Witvrouw M et al in Antiviral Research (2000), 46(3), 215-221 disclose the ability of tenofovir to delay HIV viral breakthrough after high-risk sexual exposure.
Pani A et al in Antiviral Chemistry & Chemotherapy (2001), 12(Suppl. 1), 51-59 describe the ability of lamivudine to delay viral breakthrough.
The ability of TMC278 to prevent HIV infection via sexual intercourse or related intimate contact between partners can be demonstrated in the following test. Immature monocyte derived dendritic cells (immMO-DC) represent a good model for interstitial dendritic cells, which are early targets during sexual HIV transmission and important initiators of the immune response. These immMO-DC were used in "in vitro" models to test the prevention of HIV infection via sexual intercourse or related intimate contact between partners. One such model is described in the experimental part and indicates that the TMC278 potently inhibits HIV replication in MO-DC/ CD4(+) T cell co- cultures.
Examples Example 1: Pharmacokinetics of E-TMC278 A double-blind, randomized, placebo-controlled Phase I trial was designed to evaluate safety, tolerability, and ex-vivo pharmacokinetics of single doses of compound E- TMC278 in healthy male volunteers. Oral doses of 12.5, 25, and 50 mg were formulated in PEG 400 and taken with a standard meal. The pharmacokinetic results are shown in Table 4.
The pharmacokinetic results of another double-blind, randomized, placebo -controlled Phase I study with 4 dosing sessions to evaluate the safety, tolerability, pharmacokinetics and ex-vivo pharmacodynamics of single 100 mg and 200 mg oral doses of compound E-TMC278 in healthy male subjects are also reported in Table 4. Randomization was such that for each session 6 subjects received the same dose of compound E-TMC278 and 3 subjects received placebo. There was a time interval of about 14 days between each dosing session
Table 4 shows that high and dose-proportional exposures were obtained. The correlation coefficient for the 5 Cmax datapoints is 0.9897 and for the area under the curve values between 0 and 48 hours (AUCo-48hr) 0.9952. Half- life of plasma concentrations ranged between 37 and 39 hours. The compound was well tolerated by the volunteers. No relevant adverse effects of the drug were noted.
Table 4
Figure imgf000023_0001
Example 2: Virological profile of Compound E-TMC278
Compound E-TMC278 was tested in a cell-based assay, using natural host cells of HIV. MT-4 cells (a cell line of human T cells) were infected with HIV-1 (wild type or mutants) and exposed to different concentrations of antiviral compound in the presence of 10% fetal calf serum. Cytotoxicity was determined in parallel with the antiviral activity so that the selectivity of the antiviral effect could be assessed. Active compounds have to penetrate the cell membrane in order to interfere with replication steps inside the cell.
After four days of incubation at 37°C, the viability of the HIV and mock-infected cells was assessed by an automated tetrazolium-based colorimetric assay. This method enabled the calculation of both the 50% inhibitory concentration for inhibition of viral cytopathicity (IC50), the IC90, and the 50% cytotoxic concentration (CC50). The ratio CC50/IC50, also called the selectivity index, is an indication of the specificity of the antiviral effect. Tested HIV strains included: Wild type (wt) HIV-1; a panel of single and double mutants, obtained by site-directed mutagenesis (SDM), and a panel of clinical isolates, selected for resistance against NNRTIs.
Activity towards wild type and SDM mutants A limited panel of HIV-1 mutants was constructed using site-directed mutagenesis
(SDM) and homologous recombination techniques. Compound E-TMC278 was tested against an extended panel of single and double mutants known to be resistant against commercially available NNRTIs. Nevirapine (NVP) and efavirenz (EFV) were included as controls.
The results are shown in Table 5 (values presented are IC50 values in nM). For wild type virus, the obtained IC50 was 0.4 nM (0.15 ng/ml) and the IC90 1.3 nM (0.48 ng/ml). The HIV strain with the lowest sensitivity against compound E-TMC278 within this selection was the double mutant 100I+103N, with an IC50 of about 8 nM and an IC90 of about l6 nM.
Table 5
Figure imgf000024_0001
Figure imgf000025_0001
Development of resistance in vitro
NNRTIs are highly selective inhibitors of HIV-1 but their current clinical use is limited by the rapid emergence of NNRTI (cross-) resistance. The rate of resistance emergence against compound E-TMC278 and the first generation NNRTIs nevirapine and efavirenz was compared in vitro.
MT4 cells were infected with wild type HIV-1 at high multiplicity of infection (>1 infectious virus per cell, to maximize the genetic diversity of the virus population) in the presence of various concentrations of compound E-TMC278 (40, 200, 1000 and
5000 x IC50), and were monitored twice a week for virus replication. Emerging virus was collected for pheno- and genotyping. Cultures witliout evidence of virus replication were further sub-cultivated in the presence of the same concentration of inhibitor for a total duration of 30 days (10 passages).
Resistance to nevirapine emerged within 3-6 days, at all tested concentrations.
Breakthrough virus harboured the typical Y181C mutation. The same experiments with efavirenz resulted in the selection of G190E at all concentrations (up to 5μM) within 3 to 7 days. Compound E-TMC278 did not select for resistant virus within 30 days using wild-type virus. If a double resistant mutant K103N+Y181C (IC50 0.8 nM) was used instead of wild type virus, resistance did emerge at all tested concentrations. Starting from the single mutants Y181C (IC50 1.3nM) or 103N (IC50 0.3nM), virus breakthrough did not occur at 40 and 200 nM, but did occur at 10 nM.
In this experimental setting of high genetic diversity, HIV-1, resistant to first generation NNRTIs, was selected very rapidly. Resistant viruses harboured only one mutation. In contrast, emergence of HIV-1, resistant to compound E-TMC278 was delayed or did not occur.
Cardiovascular and pulmonary safety of compound E-TMC278
Compound E-TMC278 had little or no effect on cardiovascular and pulmonary parameters in vivo at plasma levels covering and exceeding the targeted plasma levels in man and at concentrations in vitro covering or exceeding the anti- viral concentration in vitro.
Example 3: In vitro models to test the ability of compound E-TMC278 to prevent HIV infection via sexual intercourse or related intimate contact between partners.
For instance, in one model, monocyte-derived dendritic cells (MO-DC) were infected for
2 hours with the monotropic HIV strain Ba-L at a multiplicity of infection (MOI) of 10" . After infection, cells were washed 6 times and resuspended in 10% BCS at 400.000 cells/ml. Autologous CD4(+) T cells were purified out of the lymphocyte fraction of the same elutration as the MO-DC and used at a concentration of 2X 106 cells/ml ((ratio
MO-DC/CD4(+) T : 1/5).
A serial dilution of a compound of formula (I) (test compound) was added to the MO- DC/ CD4(+) T cell co-cultures. Each experiment was done in 96-well plates, in which each cup contained 50μl of MO-DC, 50μl of CD4(+) T cells and lOOμl of test compound.
Half of the culture medium, with test compound, was refreshed twice weekly.
Supernatants were analysed in ELISA after 14 days of culture. To determine antiviral activity, the test compound concentration able to suppress 50% of the viral replication at the end of the primary cultures (EC50) was measured. For compound E-TMC278, the
EC50 value was 0.55 nM.
Example 4: formulations Tablet formulation of the following composition: Emtricitabine 300 mg
Tenofovir diisoproxyl fumarate 300 mg
E-TMC278 hydrochloride salt 110 mg
HPMC 2910 15 mPa.s 24 mg Polysorbate 20 6 mg
Crosspolyvidone 18 mg
Lactose monohydrate 43 mg
Magnesium stearate 3 mg Talcum 6 mg
The active ingredients and lactose are fluidised and sprayed with a solution of HPMC and polysorbate in water (at an equivalent of 120 ml/tablet). Subsequently crosspolyvidone is added, while still being fluidised, followed by magnesium stearate and talcum. The thus obtained granulate is compressed into 13 mm cylindrical tablets using standard compressing equipment.

Claims

CLALMS
1. A combination comprising (i) 4- [[4- [[4-(2-cyanoethenyl)-2,6-dimethylphenyl] -amino] -2-pyrimidinyl] -amino]- benzonitrile, also named TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
2. The combination according to claim 1 comprising (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
3. The combination according to claim 1 comprising (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
4. The combination according to claim 1 comprising (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
5. The combination according to claim 1 comprising (i) TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; or a prodrug thereof; and (ii) a nucleoside reverse transcriptase inhibitor; and (iii) a second nucleoside reverse transcriptase inhibitor other than the nucleoside reverse transcriptase inhibitor of (ii) ; wherein TMC278 and the nucleoside reverse transcriptase inhibitors are therapeutically effective HIV inhibitors at a dose that can be administered once daily.
6. The combination according to any of claims 1 - 5, wherein TMC278 occurs in its E-isomeric form.
7. The combination according to any of claims 1 - 6, wherein the nucleotide reverse transcriptase inhibitor and/or the nucleoside reverse transcriptase inhibitor or inhibitors select mutations in the reverse transcriptase that do not cause resistance to TMC278.
8. The combination according to any one of claims 1 to 7 wherein the nucleotide reverse transcriptase inhibitor is tenofovir or its prodrug tenofovir disoproxil fumarate.
9. The combination according to any one of claims 1 to 7 wherein the nucleoside reverse transcriptase inhibitor is emtricitabine, racemic FTC, lamivudine (also named 3TC), abacavir or a pharmaceutically acceptable salt thereof.
10. The combination according to any one of claims 1 to 7 wherein the nucleoside reverse transcriptase inhibitor is emtricitabine.
11. The combination according to any one of claims 1 to 7 wherein the combination comprises (i) TMC278 or a pharmaceutically acceptable salt, and (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, and (iii) emtricitabine.
12. The combination according to any one of claims 1 to 7 wherein the nucleoside reverse transcriptase inhibitor is lamivudine.
13. The combination according to claim 8 wherein the combination comprises (i) TMC278 or a pharmaceutically acceptable salt, and (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, and (iii) lamivudine.
14. The combination according to any one of claims 1 to 7 wherein the nucleoside reverse transcriptase inhibitor is abacavir or a pharmaceutically acceptable salt thereof.
15. The combination according to calim 14 wherein the combination comprises (i) TMC278 or a pharmaceutically acceptable salt, and (ii) tenofovir or its prodrug tenofovir disoproxil fumarate, and (iii) abacavir or a pharmaceutically acceptable salt thereof.
16. The combination according to any one of claims 1 to 7 wherein the combination comprises (i) TMC278 or a pharmaceutically acceptable salt, and (ii) lamivudine, and (iii) emtricitabine.
17. The combination according to any one of claims 1 to 7 wherein the combination comprises (i) TMC278 or a pharmaceutically acceptable salt, and (ii) abacavir, or a pharmaceutically acceptable salt thereof; and (iii) emtricitabine.
18. The combination according to any one of claims 1 to 7 wherein the combination comprises (i) TMC278 or a pharmaceutically acceptable salt, and (ii) lamivudine, and (iii) abacavir, or a pharmaceutically acceptable salt thereof.
19. The combination according to any one of claims 1 to 18 wherein weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/4 to 4/1.
20. A product containing a combination as claimed in any of claims 1 to 19 as a combined preparation for simultaneous, separate or sequential use against HTV infection.
21. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as claimed in any of claims 1 to 18.
22. The formulation of claim 21 comprising as active ingredients (i) TMC278 or its stereoisomeric form or pharmaceutically acceptable salt or its prodrug, and (ii) a nucleoside reverse transcriptase inhibitor, and (iii) a nucleotide reverse transcriptase inhibitor.
23. A combination as claimed in any one of claims 1 to 18 for use as a medicine.
4. Use of a combination as claimed in any one of claims 1 to 18 for the manufacture of a medicament for the prevention of HIV infection or transmission via sexual intercourse or related intimate contact between partners.
PCT/EP2004/052028 2001-08-13 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors WO2005021001A1 (en)

Priority Applications (115)

Application Number Priority Date Filing Date Title
JP2006525150A JP5507791B2 (en) 2003-09-03 2004-09-03 Combination of NNRTI and RT inhibitor containing pyrimidine
EA200600522A EA014840B1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
CN2004800254267A CN101060844B (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
US10/570,228 US20080200435A1 (en) 2003-09-03 2004-09-03 Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
PL04787096.9T PL1663240T5 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
AP2006003551A AP2109A (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing NNRTI withRT inhibitors
NZ545306A NZ545306A (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing NNRTI with RT inhibitors
SI200432257T SI1663240T2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
KR1020137024817A KR101638999B1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
DK04787096.9T DK1663240T4 (en) 2003-09-03 2004-09-03 COMBINATIONS OF A PYRIMIDINE-CONTAINING NNRTI WITH RT INHIBITORS
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
ES04787096T ES2542017T5 (en) 2003-09-03 2004-09-03 Combinations of an NNRTI-containing pyrimidine with RT inhibitors
MXPA06002437A MXPA06002437A (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors.
AU2004268390A AU2004268390B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing NNRTI with RT inhibitors
BRPI0414027-3A BRPI0414027A (en) 2003-09-03 2004-09-03 combinations of a pyrimidine containing nnrti with inhibitors of tr
CA2537095A CA2537095C (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2577273A CA2577273C (en) 2004-09-02 2005-09-02 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
AU2005279158A AU2005279158C1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
EA200700534A EA011036B1 (en) 2004-09-02 2005-09-02 Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AP2007003933A AP2487A (en) 2004-09-02 2005-09-02 Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
SI200531539T SI1789139T1 (en) 2004-09-02 2005-09-02 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile
AU2005279157A AU2005279157B2 (en) 2004-09-02 2005-09-02 Fumarate of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl]amino)-2-pyrimidinyl)amino]benzonitrile
MX2007002595A MX2007002595A (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4- [[4 -(2-cyanoethenyl)-2, 6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile.
AT05108086T ATE508748T1 (en) 2004-09-02 2005-09-02 SALT OF 4-ÄÄ4-ÄÄ4-(2-CYANOETHENYL)-2,6- DIMETHYLPHENYLÜAMINOÜ-2- PYRIMIDINYLÜAMINOÜBENZONITRIL.
ES05108086T ES2371442T7 (en) 2004-09-02 2005-09-02 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile salt
BRPI0514861-8A BRPI0514861A (en) 2004-09-02 2005-09-02 4 - ((4 - ((4- (2-cyanoethenyl) -2,6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile furamate
RS20110355A RS51923B2 (en) 2004-09-02 2005-09-02 Salt of [[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyi]amino]-2-, pyrimidinyl]amino]benzonitrile
EP05108086.9A EP1632232B3 (en) 2004-09-02 2005-09-02 Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
KR1020077006376A KR101276571B1 (en) 2004-09-02 2005-09-02 Furamate of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
SI200531339T SI1632232T1 (en) 2004-09-02 2005-09-02 Salt of 4?á?á4-?á?á4-(2-Cyanoethenyl)-2,6-dimethylphenyl?åamino?å-2-Pyrimidinyl?åamino?åbenzonitrile
DK05108086.9T DK1632232T6 (en) 2004-09-02 2005-09-02 Salt of 4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
CN201510012919.7A CN104586850A (en) 2004-09-02 2005-09-02 Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
JP2007528885A JP4922937B2 (en) 2004-09-02 2005-09-02 4-((4-((4- (2-cyanoethenyl) -2,6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile fumarate
ES05779369T ES2384715T3 (en) 2004-09-02 2005-09-02 4 - [[4 - [[4- (2-Cyanoetenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile fumarate
DK05779369.7T DK1789139T3 (en) 2004-09-02 2005-09-02 Fumarate of 4 - ((4 - ((4- (2-cyanethenyl) -2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrile)
MEP-2011-144A ME01246B (en) 2004-09-02 2005-09-02 Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US11/219,163 US7638522B2 (en) 2001-08-13 2005-09-02 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
PCT/EP2005/054341 WO2006024667A1 (en) 2004-09-02 2005-09-02 Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CA2577288A CA2577288C (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT05108086T PT1632232E (en) 2004-09-02 2005-09-02 Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
CN2005800380936A CN101068597B (en) 2004-09-02 2005-09-02 Fumarate of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
BRPI0514871-5A BRPI0514871A (en) 2004-09-02 2005-09-02 4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile hydrochloride
AT05779369T ATE550074T1 (en) 2004-09-02 2005-09-02 FUMARATE FROM 4-((4-((4-(2-CYANOETHENYL)-2,6- DIMETHYLPHENYL AMINO -2-PYRIMIDINYL AMINO BENZONITRIL
HRP20110563TT HRP20110563T4 (en) 2004-09-03 2005-09-02 Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PCT/EP2005/054342 WO2006024668A1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
SG200905799-3A SG155885A1 (en) 2004-09-02 2005-09-02 Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
US11/574,452 US20090215804A1 (en) 2004-09-02 2005-09-02 Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
EP05779369A EP1789139B1 (en) 2004-09-02 2005-09-02 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile
PL05108086T PL1632232T6 (en) 2004-09-02 2005-09-02 Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
KR1020077006837A KR101284361B1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
JP2007528886A JP4912309B2 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4- (2-Cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
MX2007002594A MX2007002594A (en) 2004-09-02 2005-09-02 Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2, 6-dimethylphenyl) amino)-2 -pyrimidinyl) amino)benzonitrile.
EA200700536A EA013686B1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
IL173438A IL173438A (en) 2003-09-03 2006-01-30 Combinations of a pyrimidinyl-amino-benzonitrile derivative, tenofovir and optionally emtricitabine in the manufacture of a medicament given once daily to treat hiv
NO20061374A NO334877B1 (en) 2003-09-03 2006-03-27 Combinations of a pyrimidine containing NNRTI with RT inhibitors
HK06113340.4A HK1092698A1 (en) 2003-09-03 2006-12-05 Combinations of a pyrimidine containing nnrti with rt inhibitors nnrti rt
IL181650A IL181650A (en) 2004-09-02 2007-03-01 Solid pharmaceutical composition comprising a pharmaceutically acceptable carrier and hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile and use thereof in the manufacture of a medicament for treating or preventing hiv infection
IL181649A IL181649A0 (en) 2004-09-02 2007-03-01 Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino) benzonitrile
NI200700068A NI200700068A (en) 2004-09-02 2007-03-01 4 - [[4 - [[4- (2-CYANOETHENYL) -2,6- DIMETHYLPHENYL] AMINO] -2- PYRIMIDINYL] AMINO] BENZONITRILE
NI200700069A NI200700069A (en) 2004-09-02 2007-03-01 4 - ((4 - ((4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL) AMINO) -2- PYRIMIDINYL) AMINO) BENZONITRILE FUMARATE
CR9032A CR9032A (en) 2004-09-02 2007-03-30 4 - ((4 - ((4- (2-CYANETHETHYL)) -2,6-DIMETHYLPHENYL) AMINO-2- PYRIMIDINYL) AMINO) BENZONITRILE FUMARATE
NO20071745A NO340654B1 (en) 2004-09-02 2007-04-02 The hydrochloride salt of 4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
NO20071720A NO339788B1 (en) 2004-09-02 2007-04-02 Fumarate of 4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
HK08101831.3A HK1112862A1 (en) 2004-09-02 2008-02-20
US12/168,540 US7956063B2 (en) 2001-08-13 2008-07-07 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US12/574,881 US8841310B2 (en) 2003-09-03 2009-10-07 Combinations of a pyrimidine containing NNRTI with RT inhibitors
US12/845,463 US8101629B2 (en) 2001-08-13 2010-07-28 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US13/040,465 US20110150996A1 (en) 2004-09-02 2011-03-04 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino] -2-pyrimidinyl]amino]benzonitrile
AU2011201123A AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors
IL213104A IL213104A (en) 2003-09-03 2011-05-24 Combinations of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile and nucleoside or nucleotide reverse transcriptase inhibitors, compositions comprising them and uses thereof
HRP20120499TT HRP20120499T1 (en) 2004-09-02 2012-06-14 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile
US14/454,045 US20140349971A1 (en) 2003-09-03 2014-08-07 Combinations of A Pyrimidine Containing NNRTI with RT Inhibitors
NO2014031C NO2014031I1 (en) 2003-09-03 2014-12-18 (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino-2-pyrimidinyl] amino] benzonitrile (Rilpivirie) and any therapeutically equivalent form thereof protected by the patent concerned such as pharmaceutically acceptable salts of Rilpiverine including the hydrochloride salt of Rilpivirine, and Temofovir disproxil (especially Tenofovir disproxil fumarate salt).
US14/744,501 US20150283135A1 (en) 2003-09-03 2015-06-19 Combinations Of A Pyrimidine Containing NNRTI With RT Inhibitors
NL300781C NL300781I2 (en) 2003-09-03 2015-10-20
LU92853C LU92853I2 (en) 2003-09-03 2015-10-20 A COMBINATION OF RILPIVIRINE OR AN EQUIVALENT THERAPEUTIC FORM THEREFROM AS PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE RILPIVIRINE HYDROCHLORIDE SALT AND THE EMTRICITABINE
LU92855C LU92855I2 (en) 2003-09-03 2015-10-21 A COMBINATION OF RILPIVIRINE OR AN EQUIVALENT THERAPEUTIC FORM THEREFROM IN SUCH AS PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE RILPIVIRINE HYDROCHLORIDE SALT, TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE, AND THE EMTRICITABINE
BE2015C053C BE2015C053I2 (en) 2003-09-03 2015-10-21
CY2015038C CY2015038I2 (en) 2003-09-03 2015-10-21 COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS
NL300768C NL300768I2 (en) 2003-09-03 2015-10-21 Combination of rilpivirine or a pharmaceutically acceptable salt of rilpivirine, including the hydrochloride salt of rilpivirine, tenofovir disoproxil fumarate, and emtricitabine
FR15C0071C FR15C0071I2 (en) 2003-09-03 2015-10-21 COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)
CY2015039C CY2015039I1 (en) 2003-09-03 2015-10-21 COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS
FR15C0073C FR15C0073I2 (en) 2003-09-03 2015-10-21 COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)
HUS1500053C HUS1500053I1 (en) 2003-09-03 2015-10-21 Combinations of a pyrimidine containing nnrti with rt inhibitors
HUS1500052C HUS1500052I1 (en) 2003-09-03 2015-10-21 Combinations of a pyrimidine containing nnrti with rt inhibitors
HUS1500054C HUS1500054I1 (en) 2003-09-03 2015-10-21 Combinations of a pyrimidine containing nnrti with rt inhibitors
CY2015040C CY2015040I2 (en) 2003-09-03 2015-10-21 COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS
LU92854C LU92854I2 (en) 2003-09-03 2015-10-21 A COMBINATION OF RILPIVIRINE OR AN EQUIVALENT THERAPEUTIC FORM THAT IS DIRECTED THEREFROM PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE RILPIVIRINE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE
FR15C0072C FR15C0072I2 (en) 2003-09-03 2015-10-21 COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)
HK15110805.7A HK1210029A1 (en) 2004-09-02 2015-11-03 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile 4-[[4-[[4-(2-)-26-]]-2-]]
US15/383,076 US20170100398A1 (en) 2003-09-03 2016-12-19 Combinations of a pyrimidine containing nnrti with rt inhibitors
NO2016025C NO2016025I1 (en) 2003-09-03 2016-12-20
FR16C1023C FR16C1023I1 (en) 2004-09-02 2016-12-20 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile salt
LTPA2016043C LTPA2016043I1 (en) 2004-09-02 2016-12-20 4 [[4 - [[4- (2-Cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile salt
CY2016049C CY2016049I1 (en) 2003-09-03 2016-12-20 COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS
LTPA2016045C LTPA2016045I1 (en) 2003-09-03 2016-12-20 Pyrimidine combinations containing NNRTIs with RT inhibitors
HUS1600059C HUS1600059I1 (en) 2003-09-03 2016-12-20 Combinations of a pyrimidine containing nnrti with rt inhibitors
LTPA2015035C LTC1663240I2 (en) 2003-09-03 2016-12-20 PYRIMIDINE COMBINATIONS CONTAINING NNRTI WITH RT INHIBITORS
HUS1600060C HUS1600060I1 (en) 2004-09-02 2016-12-20 Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
CY2016051C CY2016051I1 (en) 2004-09-02 2016-12-20 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRIUM SALT
HUS1600058C HUS1600058I1 (en) 2003-09-03 2016-12-20 Combinations of a pyrimidine containing nnrti with rt inhibitors
LTPA2016042C LTPA2016042I1 (en) 2004-09-02 2016-12-20 4 [[4 - [[4- (2-Cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile salt
CY2016050C CY2016050I1 (en) 2004-09-02 2016-12-20 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRIUM SALT
HUS1600061C HUS1600061I1 (en) 2004-09-02 2016-12-20 Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
CY2016048C CY2016048I1 (en) 2003-09-03 2016-12-20 COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS
NO2016026C NO2016026I1 (en) 2003-09-03 2016-12-20 Combination of rilpivirine or a therapeutically equivalent form thereof such as a pharmaceutically acceptable salt of rilpivirine including the hydrochloride salt of rilpivirine and emtricitabine and tenofovir alafenamide or a pharmaceutically acceptable salt thereof, especially tenofovir alafenamide fumarate
FIEP04787096.9T FI1663240T4 (en) 2003-09-03 2016-12-20 Combinations of a pyrimidine containing nnrti with rt inhibitors
FR16C1025C FR16C1025I1 (en) 2004-09-02 2016-12-20 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile salt
NO2017063C NO2017063I1 (en) 2004-09-02 2017-11-21 Combination of: - rilpivirine hydrochloride for a therapeutically equivalent form thereof, - emtricitabine and - tenofovir alafenamide or pharmaceutically acceptable salt thereof, especially tenofovir alafenamide fumarate
NO2017065C NO2017065I1 (en) 2004-09-02 2017-11-21 Combination of rilpivirine hydrochloride or therapeutic equivalent thereof and tenofovir, especially tenofovir disproxil fumarate
US15/852,181 US20180116964A1 (en) 2004-09-02 2017-12-22 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US15/950,548 US20180228800A1 (en) 2003-09-03 2018-04-11 Combinations of a pyrimidine containing nnrti with rt inhibitors
US16/360,693 US20190216807A1 (en) 2003-09-03 2019-03-21 Combinations of a pyrimidine containing nnrti with rt inhibitors
US16/784,404 US20200171027A1 (en) 2003-09-03 2020-02-07 Combinations of a pyrimidine containing nnrti with rt inhibitors
US17/472,870 US20220008417A1 (en) 2003-09-03 2021-09-13 Combinations of a pyrimidine containing nnrti with rt inhibitors

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
US60/499,771 2003-09-03
EP03103275.8 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103319.4 2003-09-08
EP03103335.0 2003-09-10
EP03103335 2003-09-10
EP03103668 2003-10-02
EP03103668.4 2003-10-02
US50848603P 2003-10-03 2003-10-03
US60/508,486 2003-10-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/570,228 A-371-Of-International US20080200435A1 (en) 2003-09-03 2004-09-03 Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
US12/574,881 Continuation US8841310B2 (en) 2003-09-03 2009-10-07 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Publications (1)

Publication Number Publication Date
WO2005021001A1 true WO2005021001A1 (en) 2005-03-10

Family

ID=34280181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/052028 WO2005021001A1 (en) 2001-08-13 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Country Status (25)

Country Link
US (9) US20080200435A1 (en)
EP (1) EP1663240B2 (en)
JP (3) JP5507791B2 (en)
KR (1) KR20060090658A (en)
CN (1) CN101060844B (en)
AP (1) AP2109A (en)
AU (5) AU2004268390B2 (en)
BE (1) BE2015C053I2 (en)
CA (1) CA2537095C (en)
CY (5) CY2015038I2 (en)
FI (1) FI1663240T4 (en)
FR (3) FR15C0073I2 (en)
HK (1) HK1092698A1 (en)
HR (1) HRP20150798T4 (en)
HU (5) HUS1500052I1 (en)
IL (2) IL173438A (en)
LT (2) LTC1663240I2 (en)
LU (3) LU92853I2 (en)
MX (1) MXPA06002437A (en)
MY (1) MY169670A (en)
NL (2) NL300781I2 (en)
NO (6) NO334877B1 (en)
NZ (1) NZ545306A (en)
PL (1) PL1663240T5 (en)
WO (1) WO2005021001A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632232A1 (en) * 2004-09-02 2006-03-08 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
WO2006106103A2 (en) 2005-04-04 2006-10-12 Tibotec Pharmaceuticals Ltd. Prevention of hiv- infection with tmc278
WO2006135933A2 (en) * 2005-06-13 2006-12-21 Bristol-Myers Squibb & Gilead Sciences, Llc Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine
WO2006135932A2 (en) * 2005-06-13 2006-12-21 Gilead Sciences, Inc. Stable fixed-dose formulations containing a combination of antivirals, method for producing thereof using dry granulation
WO2007068934A2 (en) * 2005-12-14 2007-06-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
WO2007092326A2 (en) * 2006-02-03 2007-08-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Inhibition of hiv infection through chemoprophylaxis
WO2007082922A3 (en) * 2006-01-20 2007-09-20 Tibotec Pharm Ltd Long term treatment of hiv- infection with tcm278
EA011036B1 (en) * 2004-09-02 2008-12-30 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
WO2009115652A3 (en) * 2008-01-03 2010-01-21 Universite De La Mediterannee, Aix-Marseille Ii Bitherapy and tritherapy used for treating an hiv-positive patient
US7705148B2 (en) 2002-08-09 2010-04-27 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AP2296A (en) * 2004-09-02 2011-10-31 Janssen Pharmaceutica Nv Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
US8080551B2 (en) 2001-08-13 2011-12-20 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidines derivatives
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2012068535A1 (en) 2010-11-19 2012-05-24 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
US8841310B2 (en) 2003-09-03 2014-09-23 Janssen R & D Ireland Combinations of a pyrimidine containing NNRTI with RT inhibitors
US20140350038A1 (en) * 2011-09-16 2014-11-27 Hetero Research Foundation Rilpivirine hydrochloride
US8916558B2 (en) 2007-03-14 2014-12-23 Tibotec Pharmaceuticals Ltd. Powders for reconstitution
US9072757B2 (en) 2006-07-05 2015-07-07 Universite D'aix-Marseille Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins
US9457036B2 (en) 2003-01-14 2016-10-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP2932970B1 (en) 2010-01-27 2018-03-21 VIIV Healthcare Company Antiviral therapy
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
WO2018193470A1 (en) * 2017-04-18 2018-10-25 Cipla Limited Combination therapy for use in treating retroviral infections
US10744235B2 (en) 2009-12-21 2020-08-18 Janssen Sciences Ireland Unlimited Company Degradable removable implant for the sustained release of an active compound
US11065198B2 (en) 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
US20220079875A1 (en) * 2008-12-24 2022-03-17 Janssen Sciences Ireland Unlimited Company Implantable devices for treating hiv
RU2826218C2 (en) * 2016-10-24 2024-09-05 Янссен Сайенсиз Айрлэнд Анлимитед Компани Dispersible compositions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926068T3 (en) 2012-12-21 2022-10-21 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited Pharmaceutical compositions
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0349242A2 (en) 1988-06-27 1990-01-03 The Wellcome Foundation Limited Therapeutic nucleosides
EP0382526A2 (en) 1989-02-08 1990-08-16 Biochem Pharma Inc Substituted -1,3-oxathiolanes with antiviral properties
EP0434450A2 (en) 1989-12-22 1991-06-26 The Wellcome Foundation Limited Therapeutic nucleosides
WO1993023021A2 (en) 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
WO1996001110A2 (en) 1994-07-01 1996-01-18 Janssen Pharmaceutica N.V. Anti-hiv triple combination
WO2003016306A1 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
KR0172134B1 (en) 1990-07-19 1999-02-01 오오쓰까 아끼히코 Solid preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH07503943A (en) * 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド Cross-linked polysaccharides, polycations and lipids useful for encapsulation and drug release
JPH06316524A (en) 1992-09-11 1994-11-15 Naoyuki Inoue Anti-aids virus agent
IT1281502B1 (en) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN COMBINATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP1214059B1 (en) 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
GEP20043285B (en) 2000-03-30 2004-07-26 Bristol Myers Squibb Co Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (en) 2000-10-11 2002-04-25 Ethicon Gmbh Areal implant having a flexible basic structure on a polymer basis, contains ultrasonically detectable elements, which contain or produce gas and set up for detectability for at least four weeks after implantation
CN1487935A (en) 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� Medicinal compositions improved in solubility in water
BR0210518A (en) 2001-06-22 2004-06-22 Pfizer Prod Inc Pharmaceutical compositions of drug dispersions and neutral polymers
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
JP4822707B2 (en) 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Process for producing 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
CA2505130C (en) 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
AP1927A (en) 2002-11-15 2008-12-10 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
KR100629771B1 (en) * 2004-01-27 2006-09-28 씨제이 주식회사 Process for preparing oltipraz with diminished crystalline state or amorphous state
BRPI0511900A (en) 2004-06-08 2008-01-22 Vertex Pharma pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1632232B3 (en) 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
PL1632232T6 (en) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
KR20130030305A (en) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 Injectable nanoparticulate olanzapine formulations
TWI457136B (en) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Prevention of hiv-infection
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20060269475A1 (en) * 2005-04-11 2006-11-30 Ryu Wonhyoung Multi-layer structure having a predetermined layer pattern including an agent
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
WO2007014393A2 (en) 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
DK1981506T6 (en) 2006-01-20 2021-06-14 Janssen Sciences Ireland Unlimited Co LONG TERM TREATMENT OF HIV INFECTION WITH TCM278
CL2007001847A1 (en) 2006-06-23 2008-02-08 Tibotec Pharm Ltd INTRAMUSCULAR OR SUBCUTANEOUS PHARMACEUTICAL COMPOSITION INCLUDING TMC278 (RILPIVIRINE); PROCESS TO PREPARE THE COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF HIV INFECTION.
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (en) 2007-03-14 2009-06-24 Tibotec Pharm Ltd RECONSTITUTION POWERS THAT INCLUDE RILPIVIRINE DISPERSED IN CERTAIN POLYMERS. USE. PROCESS.
EP2175857B1 (en) 2007-07-12 2013-09-11 Janssen R&D Ireland Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
WO2010047819A1 (en) * 2008-10-24 2010-04-29 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0349242A2 (en) 1988-06-27 1990-01-03 The Wellcome Foundation Limited Therapeutic nucleosides
EP0382526A2 (en) 1989-02-08 1990-08-16 Biochem Pharma Inc Substituted -1,3-oxathiolanes with antiviral properties
EP0434450A2 (en) 1989-12-22 1991-06-26 The Wellcome Foundation Limited Therapeutic nucleosides
WO1993023021A2 (en) 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
WO1996001110A2 (en) 1994-07-01 1996-01-18 Janssen Pharmaceutica N.V. Anti-hiv triple combination
WO2003016306A1 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
ARIMILLI ET AL., ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, vol. 8, no. 6, 1997, pages 557 - 564
CHERRINGTON ET AL., INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997
CLINICAL MICROBIOLOGY AND INFECTION, vol. 9, no. 3, 2003, pages 186 - 193
FRIDLAND ET AL., ANTIVIRAL RESEARCH, 1997, pages 34
GILEAD SCIENCES INC.: "Gilead initiates study 934, a 48-week clinical trial evaluating VireadTM and EmtrivaTM versus CombivirTM", INTERNET ARTICLE, 11 August 2003 (2003-08-11), XP002314669, Retrieved from the Internet <URL:http://www.gilead.com/wt/sec/pr_1060631111> [retrieved on 20050124] *
HARRER ET AL., JOURNAL OF INFECTIOUS DISEASES, vol. 173, no. 2, 1996, pages 476 - 479
HOONG ET AL., JOURNAL OF ORGANIC CHEMISTRY, 1992, pages 5563 - 5565
INTERNATIONAL AIDS CONFERENCE IN PARIS, July 2003 (2003-07-01)
JEONG ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 2, 1993, pages 181 - 195
KUMAR ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 43, no. 3, 1999, pages 603 - 608
LANIER ET AL., INTERNATIONAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 1998
MILLER ET AL., INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998
OTTEN RA ET AL., JOURNAL OF VIROLOGY, vol. 74, no. 20, 2000, pages 9771 - 9775
PANI A ET AL., ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 12, no. 1, 2001, pages 51 - 59
PAVIA AT: "Abacavir/Lamivudine in Combination with Efavirenz, Amprenavir/Ritonavir or Stavudine", INTERNET ARTICLE, 9 July 2002 (2002-07-09), XP002274550, Retrieved from the Internet <URL:http://www.thebody.com/confs/aids2002/pavia5.html> [retrieved on 20040323] *
PERNO ET AL., ANTIVIRAL RESEARCH, 1992, pages 289 - 304
PERNO ET AL., MOLECULAR PHARMACOLOGY, vol. 50, no. 2, 1996, pages 359 - 366
ROBBINS ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 39, no. 10, 1995, pages 2304 - 2308
ROBBINS ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, no. 3, 1998, pages 612 - 617
SCHINAZI ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 36, no. 11, 1992, pages 2423 - 2431
SCHINAZI ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 37, no. 4, 1993, pages 875 - 881
SMITH ET AL., JOURNAL OF VIROLOGY, vol. 71, no. 3, 1997, pages 2357 - 2362
SQUIRES K E: "An introduction to nucleoside and nucleotide analogues.", ANTIVIRAL THERAPY. 2001, vol. 6 Suppl 3, 2001, pages 1 - 14, XP009042950, ISSN: 1359-6535 *
SUO ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 42, 1998, pages 2750 - 2758
TISDALE ET AL., ANTIVIRAL RESEARCH, vol. 20, no. 1, 1993
TISDALE ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OFSCIENCES OF THE UNITED STATES OF AMERICA, vol. 90, no. 12, 1993, pages 5653 - 5656
VAN ROEY ET AL., ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, vol. 4, no. 6, 1993, pages 369 - 375
VAN ROMPAY ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 40, no. 11 1, 1996, pages 2586 - 2591
WITVROUW M ET AL., ANTIVIRAL RESEARCH, vol. 46, no. 3, 2000, pages 215 - 221
YOUNG B: "Can Abacavir be given Once-a Day?", INTERNET ARTICLE, 16 September 2003 (2003-09-16), XP002274551, Retrieved from the Internet <URL:http://www.thebody.com/confs/icaac2003/young3.html> [retrieved on 20040323] *

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US10611732B2 (en) 2001-08-13 2020-04-07 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US10370340B2 (en) 2001-08-13 2019-08-06 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US9981919B2 (en) 2001-08-13 2018-05-29 Janssen Pharmaceutical N.V. HIV replication inhibiting pyrimidines
US9580392B2 (en) 2001-08-13 2017-02-28 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US8080551B2 (en) 2001-08-13 2011-12-20 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidines derivatives
US7956063B2 (en) 2001-08-13 2011-06-07 Janssen Pharmaceutica Nv Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7705148B2 (en) 2002-08-09 2010-04-27 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US9744181B2 (en) 2003-01-14 2017-08-29 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9457036B2 (en) 2003-01-14 2016-10-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8841310B2 (en) 2003-09-03 2014-09-23 Janssen R & D Ireland Combinations of a pyrimidine containing NNRTI with RT inhibitors
EA013686B1 (en) * 2004-09-02 2010-06-30 Янссен Фармацевтика Н.В. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
AU2005279158B2 (en) * 2004-09-02 2010-06-17 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
EA011036B1 (en) * 2004-09-02 2008-12-30 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AP2487A (en) * 2004-09-02 2012-10-03 Janssen Pharmaceutica Nv Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
AP2296A (en) * 2004-09-02 2011-10-31 Janssen Pharmaceutica Nv Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
AU2005279158C1 (en) * 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
EP1632232A1 (en) * 2004-09-02 2006-03-08 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
TWI457136B (en) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Prevention of hiv-infection
KR101360851B1 (en) 2005-04-04 2014-02-11 얀센 알 앤드 디 아일랜드 Prevention of hiv-infection
CN103860560A (en) * 2005-04-04 2014-06-18 泰博特克药品有限公司 Prevention of hiv-infection with tmc278
JP2013079275A (en) * 2005-04-04 2013-05-02 Tibotec Pharmaceuticals Prevention of hiv-infection with tmc278
US10765674B2 (en) 2005-04-04 2020-09-08 Janssen Sciences Ireland Unlimited Company Prevention of HIV-infection
JP2008534651A (en) * 2005-04-04 2008-08-28 テイボテク・フアーマシユーチカルズ・リミテツド Prevention of HIV infection with TMC278
AP2617A (en) * 2005-04-04 2013-03-18 Tibotec Pharmaceutical Ltd Prevention of HIV-infection
WO2006106103A3 (en) * 2005-04-04 2007-06-07 Tibotec Pharm Ltd Prevention of hiv- infection with tmc278
WO2006106103A2 (en) 2005-04-04 2006-10-12 Tibotec Pharmaceuticals Ltd. Prevention of hiv- infection with tmc278
AU2006231585B2 (en) * 2005-04-04 2012-02-02 Janssen Sciences Ireland Uc Prevention of HIV- infection with TMC278
EA011420B1 (en) * 2005-04-04 2009-02-27 Тиботек Фармасьютикалз Лтд. Prevention of hiv-infection with tmc278
US20220071997A1 (en) * 2005-04-04 2022-03-10 Janssen Sciences Ireland Unlimited Company Prevention of hiv-infection
WO2006135933A3 (en) * 2005-06-13 2007-05-24 Bristol Myers Squibb & Gilead Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine
WO2006135932A2 (en) * 2005-06-13 2006-12-21 Gilead Sciences, Inc. Stable fixed-dose formulations containing a combination of antivirals, method for producing thereof using dry granulation
WO2006135932A3 (en) * 2005-06-13 2007-05-24 Gilead Sciences Inc Stable fixed-dose formulations containing a combination of antivirals, method for producing thereof using dry granulation
EP2386294A3 (en) * 2005-06-13 2012-01-25 Bristol-Myers Squibb & Gilead Sciences, LLC Unitary pharmaceutical dosage form comprising Tenofovir DF
US9545414B2 (en) 2005-06-13 2017-01-17 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
EA017764B1 (en) * 2005-06-13 2013-03-29 БРИСТОЛ-МАЙЕРС СКУИББ И ДЖИЛИД САЙЭНСИС, эЛэЛСи Pharmaceutical composition, method for preparation thereof and method for treating antiviral diseases using same
US9018192B2 (en) 2005-06-13 2015-04-28 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
CN104523713A (en) * 2005-06-13 2015-04-22 吉里德科学公司 Stable fixed-dose formulations containing a combination of antivirals, method for producing thereof using dry granulation
EA017764B8 (en) * 2005-06-13 2013-05-30 БРИСТОЛ-МАЙЕРС СКУИББ И ДЖИЛИД САЙЭНСИС, эЛэЛСи Pharmaceutical composition, method for preparation thereof and method for treating antiviral diseases using same
US8598185B2 (en) 2005-06-13 2013-12-03 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
KR101151011B1 (en) 2005-06-13 2012-06-01 브리스톨-마이어스 스퀴브 & 길리드 사이언시스, 엘엘씨 Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine
WO2006135933A2 (en) * 2005-06-13 2006-12-21 Bristol-Myers Squibb & Gilead Sciences, Llc Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine
US8871271B2 (en) 2005-06-13 2014-10-28 Gilead Sciences, Inc. Method and composition for pharmaceutical product
EP2952181A1 (en) * 2005-06-13 2015-12-09 Bristol-Myers Squibb & Gilead Sciences, LLC Unitary pharmaceutical dosage form
WO2007068934A3 (en) * 2005-12-14 2008-02-21 Cipla Ltd Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
WO2007068934A2 (en) * 2005-12-14 2007-06-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
AU2006325404B2 (en) * 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
AP2936A (en) * 2006-01-20 2014-07-31 Tibotec Pharm Ltd Long term treatment of HIV-infection with TMC278
TWI458483B (en) * 2006-01-20 2014-11-01 Tibotec Pharm Ltd Long term treatment of hiv infection
JP2009526758A (en) * 2006-01-20 2009-07-23 テイボテク・フアーマシユーチカルズ・リミテツド Long-term treatment of HIV-infection with TCM278
US10953009B2 (en) 2006-01-20 2021-03-23 Janssen Sciences Ireland Unlimited Company Long term treatment of HIV-infection with TMC278
WO2007082922A3 (en) * 2006-01-20 2007-09-20 Tibotec Pharm Ltd Long term treatment of hiv- infection with tcm278
KR101501475B1 (en) * 2006-01-20 2015-03-19 얀센 알 앤드 디 아일랜드 Long term treatment of hiv-infection with tcm278
JP2013100338A (en) * 2006-01-20 2013-05-23 Tibotec Pharmaceuticals Long term treatment of hiv-infection with tmc278
EA014914B1 (en) * 2006-01-20 2011-02-28 Тиботек Фармасьютикалз Лтд. Long term treatment of hiv infection
KR101562943B1 (en) * 2006-01-20 2015-10-23 얀센 사이언시즈 아일랜드 유씨 Long term treatment of hiv-infection with tcm278
US9937191B2 (en) 2006-02-03 2018-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
WO2007092326A3 (en) * 2006-02-03 2008-12-24 Us Gov Health & Human Serv Inhibition of hiv infection through chemoprophylaxis
WO2007092326A2 (en) * 2006-02-03 2007-08-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Inhibition of hiv infection through chemoprophylaxis
AU2007212583B2 (en) * 2006-02-03 2012-12-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services, Centers for Disease Control and Prevention Inhibition of HIV infection through chemoprophylaxis
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
US9579333B2 (en) 2006-02-03 2017-02-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophyalxis
US10335423B2 (en) 2006-02-03 2019-07-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
US9072757B2 (en) 2006-07-05 2015-07-07 Universite D'aix-Marseille Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins
US8916558B2 (en) 2007-03-14 2014-12-23 Tibotec Pharmaceuticals Ltd. Powders for reconstitution
WO2009115652A3 (en) * 2008-01-03 2010-01-21 Universite De La Mediterannee, Aix-Marseille Ii Bitherapy and tritherapy used for treating an hiv-positive patient
US9545412B2 (en) 2008-01-03 2017-01-17 Universite D'aix-Marseille Composition and methods used during anti-HIV treatment
US20220079875A1 (en) * 2008-12-24 2022-03-17 Janssen Sciences Ireland Unlimited Company Implantable devices for treating hiv
US11395867B2 (en) 2009-12-21 2022-07-26 Janssen Sciences Ireland Unlimited Company Degradable removable implant for the sustained release of an active compound
US10744235B2 (en) 2009-12-21 2020-08-18 Janssen Sciences Ireland Unlimited Company Degradable removable implant for the sustained release of an active compound
EP2932970B1 (en) 2010-01-27 2018-03-21 VIIV Healthcare Company Antiviral therapy
US10426780B2 (en) 2010-01-27 2019-10-01 Viiv Healthcare Company Antiviral therapy
KR101923103B1 (en) * 2010-11-19 2018-11-28 길리애드 사이언시즈, 인코포레이티드 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
EP2826466A1 (en) 2010-11-19 2015-01-21 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate
WO2012068535A1 (en) 2010-11-19 2012-05-24 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
EA025852B1 (en) * 2010-11-19 2017-02-28 Джилид Сайэнс, Инк. THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCl AND TENOFOVIR DISOPROXIL FUMARATE
AU2016208417B2 (en) * 2010-11-19 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
US10857102B2 (en) 2010-11-19 2020-12-08 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
US20140350038A1 (en) * 2011-09-16 2014-11-27 Hetero Research Foundation Rilpivirine hydrochloride
US9233935B2 (en) * 2011-09-16 2016-01-12 Hetero Research Foundation Rilpivirine hydrochloride
US11065198B2 (en) 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
RU2826218C2 (en) * 2016-10-24 2024-09-05 Янссен Сайенсиз Айрлэнд Анлимитед Компани Dispersible compositions
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
US11234981B2 (en) 2017-04-18 2022-02-01 Cipla Limited Combination therapy for use in treating retroviral infections
WO2018193470A1 (en) * 2017-04-18 2018-10-25 Cipla Limited Combination therapy for use in treating retroviral infections
AU2018255954B2 (en) * 2017-04-18 2024-04-04 Cipla Limited Combination therapy for use in treating retroviral infections

Also Published As

Publication number Publication date
HUS1500053I1 (en) 2016-03-29
HUS1500052I1 (en) 2016-03-29
CY2015038I1 (en) 2016-08-31
JP5507791B2 (en) 2014-05-28
NO2016025I1 (en) 2016-12-20
CY2015040I1 (en) 2016-08-31
EP1663240B1 (en) 2015-04-22
US8841310B2 (en) 2014-09-23
CA2537095C (en) 2012-05-29
CY2015039I2 (en) 2016-08-31
FR15C0073I2 (en) 2016-02-12
NO2014032I1 (en) 2015-01-05
HRP20150798T1 (en) 2015-09-11
US20080200435A1 (en) 2008-08-21
US20200171027A1 (en) 2020-06-04
NL300781I1 (en) 2016-04-19
US20190216807A1 (en) 2019-07-18
NO334877B1 (en) 2014-06-23
NL300768I1 (en) 2015-12-16
CA2537095A1 (en) 2005-03-10
CY2016049I2 (en) 2017-07-12
LU92853I2 (en) 2015-12-21
NO20061374L (en) 2006-03-27
FR15C0072I2 (en) 2019-05-17
LTPA2016044I1 (en) 2017-01-10
NZ545306A (en) 2009-11-27
CY2015039I1 (en) 2016-08-31
US20220008417A1 (en) 2022-01-13
LTPA2016045I1 (en) 2017-01-10
AP2006003551A0 (en) 2006-04-30
AU2016210733A1 (en) 2016-08-25
AP2109A (en) 2010-02-26
CY2016048I2 (en) 2017-07-12
AU2004268390A1 (en) 2005-03-10
EP1663240B2 (en) 2023-03-01
MXPA06002437A (en) 2006-06-20
AU2004268390B2 (en) 2011-03-31
AU2014203484A1 (en) 2014-07-17
IL213104A0 (en) 2011-07-31
US20170100398A1 (en) 2017-04-13
IL173438A0 (en) 2006-06-11
JP5820045B2 (en) 2015-11-24
HUS1600059I1 (en) 2017-02-28
NO2014032I2 (en) 2014-12-18
PL1663240T3 (en) 2015-10-30
NO2014030I1 (en) 2015-01-05
JP2007520443A (en) 2007-07-26
FR15C0071I1 (en) 2015-04-12
LU92855I2 (en) 2015-12-21
AU2011201123A1 (en) 2011-04-07
IL173438A (en) 2012-03-29
IL213104A (en) 2016-02-29
JP2012051915A (en) 2012-03-15
CY2015040I2 (en) 2016-08-31
NO2016026I1 (en) 2016-12-20
EP1663240A1 (en) 2006-06-07
CN101060844A (en) 2007-10-24
FR15C0072I1 (en) 2015-04-12
CN101060844B (en) 2012-01-04
AU2011201123B2 (en) 2013-10-10
MY169670A (en) 2019-05-08
BE2015C053I2 (en) 2023-12-14
LTC1663240I2 (en) 2022-05-25
US20150283135A1 (en) 2015-10-08
HK1092698A1 (en) 2007-02-16
PL1663240T5 (en) 2024-02-26
US20100029591A1 (en) 2010-02-04
FR15C0071I2 (en) 2016-02-12
LU92854I2 (en) 2015-12-21
KR20060090658A (en) 2006-08-14
NL300781I2 (en) 2016-04-19
HUS1500054I1 (en) 2016-03-29
FI1663240T4 (en) 2023-04-25
US20180228800A1 (en) 2018-08-16
NL300768I2 (en) 2023-08-09
FR15C0073I1 (en) 2015-04-12
AU2014203484B2 (en) 2016-09-29
JP2015044839A (en) 2015-03-12
NO2014030I2 (en) 2014-12-18
NO2014031I2 (en) 2014-12-18
CY2016048I1 (en) 2017-07-12
CY2016049I1 (en) 2017-07-12
HRP20150798T4 (en) 2023-06-09
AU2016210733B2 (en) 2018-11-08
CY2015038I2 (en) 2016-08-31
US20140349971A1 (en) 2014-11-27
HUS1600058I1 (en) 2017-02-28
AU2019200813A1 (en) 2019-02-28
NO2014031I1 (en) 2015-01-05

Similar Documents

Publication Publication Date Title
US20220008417A1 (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2012099630A1 (en) Compositions and methods for treating or preventing a retrovirus infection
EP1159005B1 (en) Pharmaceutical combination of antiviral agents
DK1663240T3 (en) COMBINATIONS OF A PYRIMIDINE-CONTAINING NNRTI WITH RT INHIBITORS
ZA200601820B (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480025426.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004787096

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004268390

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 687/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020067003074

Country of ref document: KR

Ref document number: 545306

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12006500349

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2004268390

Country of ref document: AU

Date of ref document: 20040903

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006525150

Country of ref document: JP

Ref document number: 2537095

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10570228

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006/01820

Country of ref document: ZA

Ref document number: PA/a/2006/002437

Country of ref document: MX

Ref document number: 200601820

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2006/003551

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 200600522

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004787096

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067003074

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0414027

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 213104

Country of ref document: IL